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Problem Statement: In the collection of traditional biological samples, such as liquid 
venous whole blood, plasma, and serum, the need for phlebotomy and cold chain often 
constrains their use in complex occupational and environmental settings. Less invasive 
methods that do not require phlebotomy or cold chain, such as dried blood spots (DBS), 
provide a potential alternative to traditional samples. Despite the advantages of DBS, 
scientific questions remain as to the range of potential applications of the method, as do 
technical challenges associated with field collection. Among these challenges, the 
requirement of open-air drying, which is not currently standardized and exposes DBS 
samples to potential contaminants while creating logistical hurdles in collection and 
storage, continues to hinder wider adoption of DBS.  
 
Methods: In the first of three related manuscripts, we conducted a review of the current 
state of the science in DBS sampling using a scoping review of reviews methodology. In 
the second manuscript, we designed and demonstrated proof-of-concept for novel methods 
in field collection and storage of DBS samples. This study measured drying rates of DBS 
samples collected under novel methods through use of resistance sensors designed 
specifically for the study. In the third manuscript, we conducted a validation of assay 
protocol for comparing RNA measurements in DBS samples collected under our novel 
methods with those of the current methods recommended by the United States Centers for 
Disease Control and Prevention (CDC).  
 
 iii 
Results: In our first study, we identified approximately 2,000 (n=1,947) analytes that have 
been measured by one of more than 150 (n=169) different analytic methods. In our second 
study, we found that DBS samples collected under our novel methods in conditions of 
moderate and high humidity dried, on average, 30% and 50% faster respectively than DBS 
samples allowed to open-air dry under similar conditions as reported in the scientific 
literature. In our third study, our findings suggest that our novel methods demonstrated an 
overall improvement in performance on detection and quantification of RNA from DBS 
samples as compared with current methods. 
 
Conclusions: DBS provide researchers and practitioners a wide-ranging tool with potential 
applications for biosampling in complex occupational and environmental settings. Our 
novel methods in DBS collection and storage provide several advantages over current 
methodologies, including removal of the requirement for open-air drying of samples, 
reduced risk of sample contamination, reduced variability in environmental conditions 
incurred by samples, and overall improvements in measurements derived from DBS. Our 
findings support adoption of our novel methods in the collection and storage of DBS 
samples. 
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RATIONALE FOR RESEARCH 
 
Essential to the fields of public health and clinical medicine are the abilities to detect and 
measure potentially hazardous exposures and early indicators of adverse physiologic 
response. Measuring exposures and clinical effects both in the near-term and over the 
lifetime of individuals and populations are important contributors to advancing science and 
protecting health. In practice, exposures and their associated adverse health effects are most 
accurately measured using biological samples (biosamples), which may include blood, 
urine, and saliva among others [1]. Biosamples are also integral to the design of effective 
public health and clinical interventions, and enable practitioners to monitor, evaluate, and 
continuously improve their efforts [2]. Consequently, in the absence of biosampling, 
intervention efforts are not able to be implemented with full efficacy. Complex 
occupational and environments settings, defined here as any setting in which the ability to 
collect biosamples is limited, present an enormous challenge to the medical and public 
health communities, globally. 
 
Complex occupational and environmentally challenging settings may include surroundings 
as complex as a war zone, or as simple as a person’s home, both of which are outside of 
the traditional clinical and laboratory settings under which biological sampling is more 
easily and reliably conducted. Paradoxically, the more complex and potentially hazardous 
is the environment, the less likely are biosamples to be collected. For example, in war 
zones, where soldiers have historically been exposed to a variety of toxic chemicals, 
limitations in resources, time, and technical capacity have made the use of biosamples 
uncommon [3-4]. Beyond the military context, the need for biosampling in other 
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occupational settings is well established. For example, first responders during the Terrorist 
Attacks of September 11, 2001, many of whom developed a range of post-exposure adverse 
health conditions, were exposed to a variety of toxic chemicals, and yet few of the 
responders had any biosamples collected during the immediate response [5-6].  
 
Though firefighters were among the 9/11 first responders, a rare event such as a terrorist 
attack is not required for them to encounter hazardous chemicals. The typical working 
environment for a firefighter presents an enormous risk of hazardous chemical exposure, 
and though the Occupational Safety and Health Administration (OSHA) mandates 
biological monitoring for specific chemicals in defined work settings, routine biosampling 
programs for firefighters are not currently in place nationally [7]. It is not surprising then, 
that biosampling among other potentially hazardous occupations, such as coal miners and 
oil rig workers, is also not routine [7]. The reasons for this may vary by occupation, but 
logistical constraints involved in the collection, transport, storage, and analysis of 
biological samples are shared across occupational settings. Many of these same constraints 
extend to non-occupational settings as well. For example, there is a demonstrated need in 
low resource countries for improvements in the collection and use of biosamples [8]. Even 
simple diagnostic tests for HIV and tuberculosis are limited in many low resource settings 
[9-11]. Whether in occupational or non-occupational settings, high or low resource 
settings, there is a well-established need for overcoming the challenges associated with the 
collection of biosamples in complex environmentally challenging settings.  
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One potential solution for addressing the logistical challenges of collecting biosamples in 
environmentally challenging settings is the use of dried blood spot (DBS) sampling, which 
involve the minimally invasive collection of a small drop of blood taken from either a 
finger or heel prick and placed on specially designed filter paper for drying until the time 
of analysis [12]. DBS sampling is a minimally invasive collection method that could 
potentially be deployed in a wide variety of settings [13]. Among the advantages of DBS 
sampling, the ability to collect a biosample without the need for phlebotomy or cold chain1, 
are critical in environmentally challenging settings where such requirements often limit the 
ability to collect traditional biosamples, such as venous whole blood, plasma, and serum 
[12, 14]. DBS sampling may reduce interruptions in work flow and other challenges related 
to the collection of large volumes of blood. It also minimizes problems in sample transport 
and storage, which require more extensive inputs for maintaining integrity of traditional 
samples such as venous blood or urine.  
 
DBS samples are reported to have a wide range of diagnostic capacity and have been shown 
to have advantages over venous blood, urine and other biological samples in terms of cost, 
ease of collection, and storage [15-17]. In recent years, as advancements in the quality and 
availability of highly sensitive laboratory instrumentation have been paired with high-
powered statistical software programs, interest in the use of DBS by potential adopters has 
grown [18-20]. However, questions remain around the full range of DBS applications as 
no systematic assessment of this range is yet available in the scientific literature. What’s 
more, as researchers, practitioners, and their respective institutions consider adoption, there 
                                                     
1 Cold chain is a supply chain that is temperature controlled. Cold chain is a common requirement for 
transporting vaccines and other medical supplies that require constant refrigeration.  
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is a critical need for a more rigorous evaluation of the current state of the science in dried 
blood spots. 
 
In addition to questions regarding the current state of the science, the technical challenges 
associated with DBS use must be addressed before wider adoption can occur. Though DBS 
samples have been shown in some cases to be comparable to other biosamples in terms of 
sample stability and reproducibility, the quickly emerging fields of transcriptomics, 
proteomics, and metabolomics present unique technical challenges to the use of DBS, 
especially in field settings [21-23]. Exposure to light, moisture, and other environmental 
conditions may all impact the precision and accuracy of certain biomarkers in DBS [24-
26]. Additionally, the current protocol recommended by the United States Centers for 
Disease Control and Prevention (CDC) recommends open-air drying of DBS samples away 
from direct sunlight for a minimum of 3 hours after collection and before storage or 
transport of DBS samples [27]. In a well-resourced clinic or laboratory setting, these issues 
can be overcome; however, in complex occupational and environmental settings, the 
current protocol for DBS sampling is not sufficient. In addition to a higher risk of sample 
contamination from exposure to dust, insects and other environmental contaminants, space 
for open-air drying may not be available, and samples may need to be moved before they’ve 
been completely dried [28-29]. For DBS to be adopted more widely in complex 
occupational and environmental settings, improvements to drying methods must be 
developed and tested. In responding to the current gaps in the scientific literature, and the 
remaining technical challenges around DBS use in field settings, the objectives of this 
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dissertation was to characterize the current state of the science for DBS, and to resolve the 
issue of open-air drying in the collection of DBS samples in field settings. 
 
STUDY AIMS 
This dissertation has three specific aims and associated manuscripts: 
1. Specific Aim 1: To apply a systematic approach to characterizing the current state 
of the science in dried blood spots.  
2. Specific Aim 2: To develop and validate novel methods in DBS collection aimed 
at improving the reliability and stability of analyte measurements from DBS 
samples, especially those collected under challenging field conditions. Hypothesis: 
We hypothesize that DBS samples collected under our novel methods will have 
average drying times of less than 90 minutes in conditions of low to moderate, or 
high humidity. 
3. Specific Aim 3: To investigate the performance of our novel methods in DBS 
collection on the detection and quantification of RNA in DBS samples compared 
with the current DBS methods recommended by CDC. Hypothesis: We hypothesize 
that our novel methods in DBS collection will demonstrate an overall improvement 
in performance for the detection and quantification of RNA from DBS samples 




This body of this dissertation is comprised of three related manuscripts (chapters 2-4) 
each corresponding to one of the dissertation’s three specific aims. Chapter one serves as 
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introduction and chapter five as conclusion. The order and specific content for each 
chapter is presented in Table 1.1. 
 
Table 1.1. Dissertation structure and order of content. 
No. Title Content 
1. Introduction Rationale for Research; Specific Aims; Dissertation Structure 
2. Manuscript (Aim 1) State of the Science in Dried Blood Spots 
3. Manuscript (Aim 2) Improved Methods for Field Collection and Storage of Dried Blood 
Spots 
4. Manuscript (Aim 3) Improved Methods in the Collection of Dried Blood Spots for RNA 
Detection and Quantification 
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Background: Advancements in the quality and availability of highly sensitive analytical 
instrumentation and methodology has led to increased interest in the use of microsamples. 
Among microsample platforms, dried blood spots (DBS) are the most well-known and 
researched. While there have been a variety of review papers published on dried blood 
spots, there has been no attempt at describing and evaluating the full range of analytes 
measurable in DBS, nor any systematic approach published for characterizing the 
strengths, weaknesses, opportunities, and threats associated with adoption of the 
technology.  
 
Objective: The objective of this review was to apply a systematic approach to 
characterizing the state of science in dried blood spots. 
 
Methods: A scoping review of reviews (SRR) methodology was utilized for characterizing 
the state of the science in DBS. A snowball methodology was incorporated into the SRR 
methods in order to build a comprehensive database of analytes measured in DBS, and a 
SWOT analysis was included for describing strengths, weaknesses, opportunities, and 
threats commonly associated with dried blood spots. 
 
Results: We identified 1,947 unique analytes measured by one or more of 169 different 
analytic methods. These analytes include a broad range of biomarkers from target genes to 
transcripts to proteins and metabolites among many others. The strengths of DBS enable 
its simple application in most clinical and laboratory settings, and the removal of the need 
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for phlebotomy and cold chain handling for stable analytes can potentially expand 
biosampling to hard-to-reach and otherwise vulnerable populations. Weaknesses may limit 
adoption in the near term as DBS is a nontraditional sample and often requires conversion 
of measurements to plasma or serum values. Opportunities presented by novel instruments, 
analytic and analyte stabilization approaches, however, may obviate many of the current 
limitations of DBS, but threats surrounding privacy, security, and ethical considerations in 
the use of DBS samples must be seriously considered by those adopting the technology. 
These threats are particularly problematic to DBS due to the improved stability of residual 
samples, which hold enormous potential value for research and application for DBS 
compared with traditional samples. 
 
Conclusion: DBS provide a wide range of existing and potential applications that extend 
beyond the reach of traditional samples. Current limitations are serious, but not intractable. 





Recent advancements in the quality and availability of highly sensitive analytical 
instrumentation has led to increased interest in the use of microsamples (i.e., biological 
samples of less than 50 microliters) [13, 18, 23]. Microsamples have been applied for basic 
research, public health, and clinical medicine [1, 5, 32-35]. Interest in microsampling has 
been driven, in part, by the development of sophisticated computer software programs and 
methodological platforms for improved qualitative and quantitative analysis [16, 38, 40, 
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73]. Among microsampling methods, dried blood spots (DBS), are the most well-known 
and researched. DBS are a minimally invasive method for the collection of small quantities 
of whole blood from finger or heel stick with application to specially prepared filter paper 
for drying [12, 22]. DBS samples do not require phlebotomy, and DBS can be stored and 
shipped under ambient conditions, although a comprehensive assessment of analyte 
stability has not been performed [43-44]. Existing stability studies for DBS, while limited, 
have also demonstrated a wide range of analyte stability even among similar storage 
conditions [84]. 
 
To date, DBS has a range of applications in clinical practice, basic research, and 
population-based research [1, 5, 22, 62, 70]. The most common and widely accepted 
clinical use of DBS is for newborn screening programs, which are primarily concerned 
with the detection of metabolic disorders [10]. Other clinical applications in the published 
literature have focused on HIV surveillance, therapeutic drug monitoring, and clinical 
chemistry [4, 10, 20, 28, 34]. Basic research applications for DBS, include biomarker 
development and validation, drug discovery and development, forensic science, systems 
biology, and toxicology [5, 9, 17, 44, 60]. Population-based research applications are 
variable, but may be broadly categorized into human epidemiological studies, including 
environmental population studies [5, 7, 44, 49].  
 
As interest in DBS methodologies continues to increase, potential adopters will need to 
quickly, effectively, and systematically assess the utility of DBS for their respective 
purposes. Understanding strengths and weakness, as well as potential opportunities and 
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threats, is essential for adopters to avoid false starts and ensure effective and appropriate 
adoption of DBS sampling to a specific goal. Furthermore, a comprehensive list of current 
and potential analytes, as well as their respective analytic methods, could help adopters 
assess the potential of DBS. While there have been a variety of review papers published on 
DBS methods, there has been no systematic assessment of the strengths and weaknesses of 
DBS, and attempts at compiling a comprehensive list of analytes validated in DBS have 
been limited in scope. 
 
The objective of this review was to apply a systematic approach to characterizing the state 
of the science in DBS for public health and medicine. We aimed to characterize the state 
of the science through identification of strengths, weaknesses, opportunities, and threats; 
and by compiling a comprehensive list of analytes and their respective analytic methods as 




A scoping review of reviews (SRR) is commonly used for identifying relevant evidence 
and mapping key concepts within a research area or domain when the available literature 
is vast and/or diverse [76]. Different from a systematic review, which typically focuses on 
a weight-of-the-evidence approach to a specific question, a scoping review does not 
attempt to “weigh” the evidence, and instead aims to identify the nature and extent of 
research around a broad question or field of science [77]. A seminal paper on scoping 
reviews in 2005 by Arksey and O’Malley defined unique stages for conducting scoping 
reviews [76]. These methods were further revised in a recent publication in 2015 by 
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Goertzen et al. which adapted the Arksey and O’Malley methods and put forward a 
protocol for conducting SRRs [78]. Goertzen et al. defined 5 stages, including:  
1. Stage 1: Establishing the Research Questions 
2. Stage 2: Identifying Relevant Studies 
3. Stage 3: Study Selection 
4. Stage 4: Charting the Data 
5. Stage 5: Collating, Summarizing, and Reporting the Results 
 
Consistent with the common uses of SRRs identified in the Arksey and O’Malley paper, 
our study aims to summarize the state of the science for dried blood spots (DBS), a topic 
with a wide range of applications. Our review characterizes the state of the science around 
DBS for policy makers, researchers, and practitioners that may otherwise lack the time, 
resources, or expertise to undertake such an endeavor [79].  
 
To this end, we adapted the Goertzen et al. methods for use in our study. The Goertzen et 
al. methods have been modified to include: 1) snowball methods and SWOT (strengths, 
weaknesses, opportunities, and threats) methods for use in data extraction (Stage 4: 
Charting the Data); and 2) a form of quality assessment, (Stage 5: Collating, Summarizing, 
and Reporting the Results). We have included these modifications in response to a recent 
paper by Levac et al. aimed at advancing the methodology in SRRs [80]. The Levac et al. 
study identified the lack of quality assessment in study selection and the poorly defined 
analytical methods in charting the data as methodological challenges to SRRs [80]. A 
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rigorous and iterative approach to each stage, consistent with current SRR methods and 
with the stated modifications, is described below. 
 
Stage 1: Establishing the Research Questions 
We began our study with a general question, “What is the current state of the science for 
DBS in the published scientific literature?” After a preliminary search of the literature 
identified a broad range of domains and applications and consultation with subject matter 
experts in academia and government, we decided to limit our study to the following 
research questions: 
1. What analytes have been measured in DBS and with which analytic methods? 
2. What strengths, weaknesses, opportunities, and threats are commonly cited for 
DBS? 
 
Stage 2: Identifying the Relevant Studies 
The search process was conducted under the guidance of the medical librarian at Johns 
Hopkins University (JHU). A preliminary search of the literature was conducted on 3 
September 2015, in 4 electronic databases, including PubMed, Embase, Toxline, and 
SciFinder. The preliminary search was designed to capture all DBS-related publications in 
the scientific literature within the databases selected.  The preliminary search yielded 
27,850 citations; 17,589 after duplicates were removed.  
 
After review of the preliminary search (Appendix A, Search Strategy, Supplementary 
Materials), we determined our search strategy was too broad to characterize the state of the 
 19 
science and map key concepts in DBS, and decided to limit our search strategy to include 
only review papers and/or validation/evaluation studies involving DBS. No search limiters 
for language or publication date were included in the final search strategy. Our final search 
took place on 16 November 2015, in 3 electronic databases, including PubMed, Embase, 
and SciFinder. In total, 2,776 citations were identified; 1,178 citations after duplicates were 
removed (Figure 2-1). 
 
Stage 3: Study Selection 
Search terms, limiters, databases, strategy by database, and inclusion/exclusion criteria are 
provided in Table 2-1. All citations identified in our final search were imported into the 
web-based bibliographic manager EndNote, and exported for uploading to Covidence, a 
web-based software program for managing literature reviews. We used Covidence for 
title/abstract and full text review. Title/abstract review included a dual review process with 
each reviewer blinded to the other reviewer’s decision. Conflicts were resolved by a third 
reviewer. During title/abstract review, we selected only reviews, commentaries/short 
reports, or technical reports involving a broad category or domain of DBS. We included 
citations involving either human or animal subjects as long as animal subjects research had 
an explicitly stated relevance to human health. We excluded citations in which DBS were 
not a focus of the study.  
 
Upon completion of title/abstract review we requested full text PDF files from the medical 
librarian. Publications not available directly through JHMI were requested through an 
interlibrary loan. Full text PDF files were uploaded to Covidence for completion of full 
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text review. Inclusion/exclusion criteria were confirmed during full text review and 
citations in which the full text was not available in English were excluded. Full text review 
included a dual review process with each reviewer blinded to the other reviewer’s decision. 
Conflicts were resolved by a third reviewer. Due to the variability in the types of studies 
included in scoping reviews, and consistent with accepted SRR methodologies, no formal 
quality assessment component was included during study selection; however, a type of 
quality assessment, as described under Stage 5, was included during our review [77]. 
 
Stage 4: Charting the Data 
Charting the data involves identification of key issues and themes found within information 
obtained from research reviewed in the SRR. Publications identified as relevant during full 
text review were included in this process. Charting the Data was completed in 2 phases, 
each conducted with two reviewers blinded to each other’s work. After each phase, 
reviewers compared and reconciled findings. If differences could not be reconciled 
between the two reviewers, a third investigator made a final decision. Phase I of Charting 
the Data is designed to address the first research question: What analytes have been 
measured in DBS and with which analytic methods? 
 
Investigators utilized a ‘snowball’ technique for Charting the Data pertaining to analytes 
measured in DBS. Specifically, if an analyte was cited as has having been measured in 
DBS, investigators followed citations until the source material (i.e., original research) was 
identified. Once the original research had been identified, investigators extracted the 
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following information: analyte name, analytic method, SRR MLA stem citation, and 
source/original research MLA citation. 
 
In order to improve the comprehensiveness of the analyte database, investigators cross-
referenced the snowballed database with original research studies identified from the final 
search strategy and excluded at the title/abstract review stage. Analytes measured in DBS 
identified through these studies and not already found in the database were added. Phase II 
of Charting the Data is designed to address the second research question: What strengths, 
weaknesses, opportunities, and threats are commonly cited for DBS? 
 
Phase I utilizes SWOT methods for extraction. Though not yet commonly used in public 
health and medicine, SWOT methods were originally developed by the business 
community to enable strategic planning [81-82]. We selected these methods for their 
potential to aid policy makers, researchers, and practitioners in considering adoption of 
DBS for their respective purposes. SWOT provides a systematic approach to identification 
and review of both intrinsic issues (i.e., strengths and weaknesses) and extrinsic issues (i.e., 
opportunities and threats) as they pertain to a particular subject; in this case, DBS. 
Furthermore, the selection of a systematic method for conducting our review directly 
addresses one of the key limitations of SRRs: lack of a well-defined method for extraction 
of information. SWOT methods for extraction were applied to each included study 
individually during Phase I, and utilized an extraction table prepared by study investigators, 
which included the following items: first author and year, title, MLA citation, study type, 
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study purpose, study conclusions, strengths, weaknesses, opportunities, threats, and 
additional comments. 
 
A component of quality assessment was included at this stage. Specifically, investigators 
reviewed the source reference (i.e., original research) cited for all information identified 
for SWOT extraction. Upon review, if the source material cited did not support the 
conclusion made in the publication reviewed in the SRR, this information was excluded 
from the SWOT extraction table. 
 
Stage 5: Collating, Summarizing, and Reporting the Results 
Upon review of the analyte database formed by the snowball extraction methods, analytes 
and analytic methods were given classifications. Analytes were classified as small 
molecule (molecular weight < 900 Daltons), large molecule (molecular weight =/> 900 
Daltons), nucleic acid (i.e., DNA or RNA) or element. After review of all unique analytic 
methods identified in the literature, we devised broad categories of analytic methods as 
follows: mass spectrometry (MS), immunoassay, nucleic acid based, separation 
(chromatography), separation (electrophoresis), separation (other), spectroscopy, and 
other. Our classifiers were informed by a review of current relevant literature. A final 
analyte database with classified analytes and methods was then imported into Stata for 
calculation of the following: (1) total number of unique analytes, (2) number of unique 
analytic methods, (3) number of unique analyte-analytic method combinations, (4) percent 
of analytes by class, (5) percent of analytic methods by category, and (6) percent of unique 
analyte-analytic methods by method category. 
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Upon review of each included study SWOT extraction table, two investigators blinded to 
each other’s work reviewed the SWOT tables to build a separate, summary SWOT table 
including common or reoccurring strengths, weaknesses, opportunities, and threats across 
all included studies. Investigators then compared their tables and rectified differences into 




Of the 1,178 citations identified for screening, 75 studies were selected for inclusion in 
the review (Figure 2-1). There were 62 review papers, 11 commentaries or short reports, 
and 2 technical reports included (Table 2-2). 
 
Phase I - Analyte Database 
We identified a total of 1,947 unique analytes in the literature to have been measured in 
DBS. A comprehensive list of analytes divided by class is provided in Table 2-3. Of the 
1,947 unique analytes measured, 48% (n=942) were classified as ‘Small Molecule’, 34% 
(n=670) as ‘Large Molecule’, 16% (n=306) as ‘Nucleic Acid’, and 2% (n=29) as ‘Element’ 
(Figure 2-2). In terms of the range of analytes identified in the literature, Table 2-3 includes 
genomic, epigenomic, transcriptomic, proteomic, and metabolomic markers. In the area of 
infectious diseases, Table 2-3 includes analytes for viral, bacterial, parasitic, and protozoan 
detection [49, 57]. Additionally, Table 2-3 includes a wide range of analytes classified as 
markers of exposure as well as health and disease status [5, 7, 10, 33, 49].  
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We identified a total of 169 unique analytic methods in the literature to have been applied 
to DBS samples for bioanalysis. All major categories of common analytic methods were 
identified, including mass spectrometry, immunoassay, nucleic acid based methods (e.g., 
polymerase chain reaction), chromatography, electrophoresis, and spectroscopy among 
others. A comprehensive table of analytic methods divided by category of method is 
provided in Table 2-4. Of the 169 analytic methods applied, 33% (n=55) were measured 
by methods classified as ‘Mass Spectrometry’ (MS), 23% (n=38) as ‘Immunoassay’, 12% 
(n=21) as ‘Nucleic Acid Based’, 12% (n=20) as ‘Separation (Chromatography)’, 5% (n=8) 
as ‘Separation (Electrophoresis)’, 2% (n=4) as ‘Separation (Other), 7% (n=12) as 
‘Spectroscopy’, and 7% (n=11) as ‘Other’ (Figure 2-3). Methods identified as ‘Other’ 
included culture based assays (n=3), enzyme based assays (n=2), precipitation assays 
(n=2), and electric potential (n=1). 
 
While an examination of the unique analytic methods applied to DBS may help 
characterize the range of potential DBS applications, it does not necessarily characterize 
common practices in the literature. It is important to note that many of the analytic methods 
in Table 2-4 were applied infrequently, while others were applied routinely. For example, 
Indirect Potentiometry was applied only once for the purpose of measuring a single analyte, 
ceruloplasmin; while Mass Spectrometry was applied to nearly 300 (n=292) large molecule 
analytes alone. In order to better characterize common DBS applications in the literature, 
we also examined the combination of unique analytes with their respective analytic 
methods. We found 3,073 unique analyte/analytic method combinations. Of the 3,073 
combinations, 61% of analytes (n=1,867) were classified as having been measured by 
 25 
‘Mass Spectrometry’ (MS), 18% (n=542) by ‘Immunoassay’, 12% (n=366) by ‘Nucleic 
Acid Based’, 6% (n=196) by ‘Separation (Chromatography)’, 1% (n=17) by ‘Separation 
(Electrophoresis)’, 0.5% (n=12) by ‘Separation’ (Other), 2% (n=50) by ‘Spectroscopy’, 
and 1% (n=23) by ‘Other’ (Appendix B - Analyte Database, Supplementary Materials). 
 
A complete list of all analytes with their corresponding analytic methods, classifications, 
SRR stem references, and original research references can be found in the Analyte 
Database provided in Appendix B under Supplementary Materials.  
 
Phase II - SWOT Analysis 
For the purposes of this investigation, only those strengths, weaknesses, opportunities, and 
threats, that are specifically relevant to DBS, are provided in Table 2-5. The SWOT 
analysis applies to the most common type of DBS sampling (i.e., sampling by finger or 
heel stick followed by direct application to filter paper cards with ambient storage). Though 
it is possible to use blood collected by venipuncture for volumetric application of blood to 
filter paper cards, as well as cold storage to improve analyte stability, these modifications 
remove several of the key advantages of DBS methods, namely sampling without need for 
phlebotomist or cold chain. 
 
Strengths 
DBS sampling is minimally invasive, requires only a small volume of blood (i.e., < 50 uL), 
and utilizes simple collection methods (i.e., no centrifugation for plasma preparation prior 
to storage) [1, 12, 46]. DBS sampling typically involves prick of a finger or heel with a 
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small lancet followed by application of several drops of blood to filter paper cards for 
drying and storage. One of the key advantages to DBS sampling is the ability to derive a 
volumetric amount of blood from a non-volumetric application to filter paper [64]. This is 
achieved by punching a fixed diameter cylinder for analysis from a portion of the dried 
spot that is assumed to be fully saturated on the filter paper. This ability to derive a 
volumetric amount blood combined with minimally invasive methods, small sample 
volume, and simple collection, allow DBS to be collected in the absence of a trained 
phlebotomist or lab, and may enable self-sampling as well as sampling outside of the 
traditional clinic or lab setting [23-24, 34]. In terms of human sampling, these strengths 
make DBS a preferred method for collecting blood from difficult to sample populations, 
such as neonates, the elderly, persons with damaged veins, or persons in remote or under-
resourced environments [7, 32, 34]. In terms of sampling from animals, DBS can allow for 
reduction and refinement in the use of small or juvenile animals [1-2, 6]. For example, by 
reducing the quantity of blood collected and the invasiveness of the method, DBS use in 
toxicological studies can allow for serial sampling from the same animal, which reduces 
the total number of animals required, and allows researchers to no longer rely on composite 
profiles2, which improves overall data quality [29, 35, 55]. 
 
The dried matrix of DBS samples inactivates most pathogens and thereby reduces 
biohazard risks associated with samples in transport [9, 31, 32, 75]. Reductions in 
                                                     
2 Composite profiles are commonly used in toxicological studies involving small or juvenile animals. 
Composite toxicological profiles are generated by combining toxicological data from multiple animals in 
order to simulate repeat sampling (i.e., serial sampling) from a single subject. They are often necessary 
when regulatory requirements limit blood sample volume or when the sample volume itself necessitates 
terminal sampling. In either of these cases, investigators are unable to conduct serial sampling, which 
diminishes data quality. 
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biohazard risks combined with simple methods in storage and transport (i.e., ambient 
conditions, no dry ice required) have allowed DBS to be considered exempt, non-regulated 
materials and are therefore not subject to hazardous material regulations in shipping [46]. 
Materials required for DBS sampling are relatively low cost, and have few material inputs 
and waste [22, 36, 66]. When taken together, the reduction in material inputs and waste, 
low cost, ambient storage and transport, simple collection, and minimally invasive 
methods, make DBS a suitable matrix for biosampling in large and/or complex population-
based studies [5, 44]. 
 
DBS samples are compatible with most bioanalytical methodologies, which allows existing 
labs to easily adopt the technology with only minor modifications to their workflow [16]. 
Aside from a hole punch device to remove a portion of sample for processing, all other 
material requirements for analyzing DBS samples should be readily available in most labs 
[43]. DBS are also a versatile sample matrix. For example, anything that can be measured 
from liquid whole blood, plasma, or serum can, in principle, be measured in DBS [11]. 
Analytes representing a wide range of physicochemical properties have already been 
validated. To date, DBS samples have been used for a variety of viral, bacterial, protozoan, 
and helminthic agents [49]. DBS have also been used to measure DNA, RNA, antibodies, 
proteins, drugs, metabolites, and an assortment of environmental contaminants among 
other analytes (Table 2-3).  
 
DBS as a method has been demonstrated to achieve similar levels of precision and 
reproducibility to that of traditional larger volume venous blood collection in vacutainer 
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tubes or capillary pipettes [11, 43]. Compared with liquid samples, several analyte classes 
in DBS have shown improved stability. For example, analytes susceptible to degradation 
due to hydrolysis, photolytic processes, and esterase as well as RNAase action [3, 7, 29, 
57, 68]. Consequently, analyte stability in DBS compared with liquid samples is 
particularly pronounced for traditionally unstable analytes such as RNA, cytokines, and 
several classes of drug metabolites [41, 54, 62, 66]. 
 
The Center for Disease Control and Prevention (CDC) have established an independent 
quality control program, CDC’s Newborn Screening Quality Assurance Program (NSQAP) 
[46]. NSQAP provides strict guidance to manufacturers and end-uses of DBS cards and 
helps to improve sensitivity and reproducibility of filter paper [43]. In addition to NSQAP, 
DBS have easy to understand federally established guidelines for collection and shipment 
[46]. Though no federal or international bioanalytical validation methods have yet been 
fully established, DBS validation methods were recommended in 2011 by the European 
Bioanalysis Forum (EBF) [45, 55, 59, 75]. 
 
Weaknesses 
It is important for potential adopters to understand that DBS is not the same thing as 
traditional plasma or serum (Table 2-6). Differences between sample types may limit 
comparability of measurements from DBS and constrain their utility in public health and 
medicine. Differences of note between DBS and plasma or serum include the following: 
DBS comes from capillary blood versus venous blood; consists of whole blood versus 
centrifuged plasma or serum; is dried versus liquid or frozen; is typically less than 50 uL 
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versus several milliliters; requires open air drying prior to ambient storage versus 
immediate cold storage; is analyzed with modified protocols versus those which were 
originally designed for plasma or serum; and often has converted or adjusted measurement 
as compared to direct measurement for traditional samples [43-44, 49, 55, 57]. Each of 
these differences present the opportunity to introduce bias into converted measurements 
taken from DBS samples, and while DBS has often been successfully adjusted to 
corresponding plasma and serum values, the underlying assumptions for a valid adjustment 
must be validated before DBS can be reliably used [45, 54]. 
 
The small volume of blood in DBS requires highly sensitive analytical instrumentation for 
accurate quantification, and may limit DBS utility for repeat testing [45, 54]. The collection 
of DBS, while simple methodologically, may also be constrained by cold or dehydrated 
patients whereby the amount or viscosity of the blood can be problematic for application 
to filter paper cards through uneven saturation of the filter paper and ultimately inaccurate 
estimation of starting volume from a fixed diameter punch [5, 7]. As previously mentioned, 
DBS samples require open-air drying for a minimum of 2-3 hours before storage [47]. This 
is problematic for a several reasons. First, open-air drying may confound analyte 
measurements due to contamination, especially when the analyte of interest is DNA or an 
environmental contaminant [55]. Second, drying cards under open-air conditions requires 
extra space for drying racks and can be problematic in field-based collection [6]. Third, 
drying rates vary and are impacted by surrounding temperature and humidity conditions, 
which are particularly problematic in tropical, humid environments [22, 43]. The rate of 
drying not only impacts the ability to store samples in a reasonable time frame, but also 
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alters analyte measurements, especially for metabolites and other analytes susceptible to 
degradation by hydrolysis, as metabolism as well as hydrolytic processes will continue 
within the blood on the filter paper card and are not quenched until moisture has been 
removed from the spot [53-54]. It should also be noted that while most pathogens are 
inactivated by drying, some pathogens such as dengue, hepatitis B, and group A 
streptococci remain active for several days after drying [49, 57-58]. 
 
Manual DBS methods for processing and bioanalysis are time and labor intensive [56, 72]. 
DBS requires a series of preparation steps, including punching discs from cards, elution 
and extraction, filtration, and in some instances chemical derivatization [72-73]. These 
steps each add cost and complexity to DBS adoption. For example, use of punch devices 
for collecting fixed diameter discs from DBS cards for analysis may cause contamination 
if devices are not adequately cleaned between punches (i.e., carry-over effects) [27, 42]. 
Some steps, like the addition of an internal standard (IS) or sample dilution, may cause 
problems for traditional samples, but they also present challenges unique to DBS due to 
the use of a dried matrix [49]. For example, an IS cannot be added to blood and 
homogeneously mixed before bioanalysis when sampling directly by finger or heel stick, 
and while an IS may be added to the extraction solvent, this does not account for issues 
arising prior to extraction [3, 11]. In terms of storage, as DBS samples are typically stored 
under ambient conditions, they are more susceptible to extreme environmental conditions 
such as high temperature and humidity [75]. These conditions, if not properly managed, 
can facilitate bacterial growth and enhance the rate of analyte degradation rendering DBS 
sample results unreliable [53, 55].  
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The most commonly cited weakness of DBS is the hematocrit effect, which is the impact 
of varying percentages of red blood cells in whole blood spotted to filter paper [14-15]. 
High or low hematocrit has two primary issues. First, hematocrit can affect the blood-to-
plasma ratio for target analytes, which can alter their measurements and bias any attempt 
at conversion from DBS to plasma [45, 74]. Second, hematocrit directly affects the 
viscosity of blood and can thus affect how a spot spreads and saturates filter paper, which 
in turn limits volumetric extraction of blood from a set diameter punch as well as extraction 
recovery [55-56]. In addition, or in combination with hematocrit effects, DBS 
measurements can be impacted by chromatographic or matrix effects within the filter paper 
card itself, which can lead to uneven spreading of blood or distribution of analytes within 
a spot depending on their particular physicochemical properties [54, 72]. Sample 
heterogeneity is also a particularly unique issue for DBS [55, 59]. Traditional liquid 
samples can be easily mixed to achieve a homogenous sample matrix, but DBS are a dried 
matrix, and when a portion of a spot is punched out from filter paper, lack of homogeneity 
within the spot can lead to different analyte measurements depending upon the location of 
the punch [30].  
 
Differential analyte stability and degradation rates, as well as extraction efficiency, are not 
unique to DBS. However, open air drying and ambient storage is unique, and can 
exacerbate issues of differential analyte stability, degradation, and extraction [3, 6]. For 
example, measurement of analytes susceptible to oxidation can be impacted by 
atmospheric oxygen during drying, and extreme temperature or humidity conditions will 
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often have differential effects on analytes of different classes [74]. A major concern 
regarding analyte stability in DBS involves the inability to retain and detect volatile organic 
compounds (VOCs) in DBS samples [7, 55]. VOCs are often lost during drying, limiting 
the ability of investigators to measure VOCs from DBS, which in turns limits the utility of 
DBS for environmental studies [7]. Beyond stability of analytes, the matrix itself can be 
problematic in analysis. The added addition of filter paper to the matrix presents a 
challenge in bioanalysis as the filter paper can cause matrix effects at the point of analysis 
[45, 53, 63, 68]. For example, ion suppression is a commonly cited issue for DBS samples 
measured by mass spectrometry [48, 52].  
 
Another relevant issue for potential adopters is the incomplete and emerging regulatory 
landscape for DBS. The current Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) guidelines for traditional samples are inadequate for DBS as 
bioanalytic validation of dried blood spots may require consideration of several additional 
parameters [29]. Added validation parameters may include type of card, volume applied to 
filter paper, homogeneity of spotting, effects of hematocrit, and comparison with gold 
standard traditional samples to name a few [45, 54, 59]. At present, FDA does not accept 
DBS as a stand-alone sample matrix and requires bridging studies for comparing DBS with 
traditional samples, which adds cost and work to adopters [59]. Lastly, of the assays 
validated in the literature, there is a wide range in quality of validation and often no 





A European Directive and concerns from US federal agencies have put pressure on 
researchers and drug developers to comply with the three 3Rs (i.e., reduction, refinement, 
replacement) in the use of animal subjects and may lead to wider adoption of DBS in 
preclinical and toxicology studies [6]. As stated previously, DBS can reduce the number 
of, and stress to, animal subjects in research and development [6, 60]. Other forces that 
may encourage DBS adoption are the trends toward centralization of labs and an increase 
in demand for outpatient or off-site clinical services [24]. As larger centralized lab facilities 
adopt DBS, the quality and availability of DBS analysis should improve. Furthermore, 
DBS are particularly suited to non-clinic or lab-based settings that may enable their use for 
off-site services such as home-based sampling [5, 32].  
 
Traditionally, analytical instrumentation has lacked adequate sensitivity for accurate 
measurement of small quantity biosamples, but recent advancements in highly sensitive 
instrumentation such as LC-MS/MS and Digital Droplet q-PCR have helped resolve these 
issues [48-49]. Exponential reductions in the cost of sophisticated instruments have led to 
greater availability of the necessary methodologies for accurate use of DBS, and may also 
encourage adoption [41-42]. As interest has continued to grow, computer-based, robotic 
automation of DBS methods in bioanalysis have also emerged and can help resolve many 
of the issues of labor intensive methods involved in DBS [54, 72]. At present, there are a 
range of semi- and fully-automated systems commercially available for dried samples 
matrix processing and bioanalysis [54, 64]. Recent advancements in microfluidics and 
nanotechnology may also provide the next generation of DBS technology, and have already 
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been applied to DBS for achieving high-fidelity blood droplet manipulation without the 
need for manual intervention [14, 16, 54]. Such advancements can help resolve 
traditionally problematic issues in DBS, such as hematocrit and chromatographic or matrix 
effects. For example, membrane filtration technology has been designed into filter paper 
cards for filtering out a volumetric amount of plasma from a non-volumetric amount of 
whole blood taken from a finger stick [41, 45, 71]. Use of membrane filtration cards can 
simultaneously minimize the effects of hematocrit, while also providing plasma from 
whole blood without the need for centrifugation [41, 45]. 
 
The emergence of ‘online’ or direct analysis methods for DBS provide several advantages 
over traditional methods; namely, the removal of the need for punching or elution [42, 45]. 
Several technologies for online analysis are currently available, including desorption 
electrospray ionization (DESI), direct analysis in real time MS (DART), and paper spray-
MS technologies [13, 26, 42, 45]. Though these methods have been shown to be less 
sensitive than off-line manual methods, their sensitivity has shown recent improvements 
[13]. Researchers have also improved microsample measurements from the data analytics 
side. For example, the use of endogenous indicators such as potassium have been used in 
DBS for estimating blood hematocrit and adjusting analyte measurements accordingly [14-
15]. Furthermore, as multiplex platforms such as MS have become more routinely used, 
the use of multi-analyte molar ratios in clinical diagnostics have been demonstrated to be 
an effective data analytics approach for reducing variability and improving diagnostic 
performance. For example, diagnosis of phenylketonuria (PKU) from DBS samples in 
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newborn screening can be achieved by examining the relative amounts of phenylalanine 
with those of tyrosine or leucine [10]. 
 
Requirements of traditional blood sampling (i.e., phlebotomy and cold chain) have often 
precluded the use of biosampling in hard-to-reach or otherwise vulnerable populations. Use 
of DBS can help facilitate sampling within these populations without the need for 
phlebotomy or cold chain [33, 65]. What’s more, DBS is particularly well-suited for use in 
large complex study designs where sampling may occur in multiple sites over an extended 
period of time [5, 36]. DBS provide a cost effective and logistically feasible method for 
such studies. DBS may also provide a viable sampling method for field-based forensics 
where proximity in time-to-events such as driving while under the influence or homicide 
may be important for obtaining accurate measurements from blood [9, 53-54, 60]. Finally, 
DBS techniques which yield a stable biosample in a dried matrix under ambient storage 
may also be applied to a variety of other kinds of biological samples, such as saliva, urine, 
or tissue [45]. 
 
Threats 
Biobanking of DBS samples and their suitability for DNA analysis present a privacy and 
ethical dilemma around proper use of residual samples [47, 52]. This threat is enhanced by 
the predominant use of DBS for newborn screening, which are collected from newborns 
for metabolic screening purposes, but which can provide a wide range of applications 
beyond their intended use [25, 47]. Residual samples from newborn screening programs 
may afford researchers a powerful tool for retrospective study. However, serious questions 
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remain as to whether mothers could or should be adequately consented for use of their 
newborn child’s DBS sample months to years after collection. Perceived improper use can 
and has led to public outrage and the mandated destruction of millions of residual DBS 
samples. For example, a settlement reached in Texas with a civil rights group led to the 
destruction of more than 5 million residual DBS samples [25]. DBS has also been put 
forward as a preferred sampling matrix for pediatric populations, but the potential 
enrollment of children in research studies could result in similar public outrage, particularly 
in the event of adverse health outcomes associated with pediatric clinical trials [50]. 
 
Another threat to DBS adoption is the dominance of traditional samples such as liquid 
plasma and serum in public health and medicine [28, 32, 40, 44]. Established labs are 
highly automated and are optimized for traditional samples [31]. Consequently, advantages 
of DBS may be overcome by resistance from labs due to the convenience and familiarity 
of using traditional samples. The lack of availability of a lab experienced with DBS 
samples may also constrain DBS use by researchers and clinicians [44]. If potential 
adopters cannot readily find an experienced lab for DBS bioanalysis, or if existing labs are 
unable to handle the added workload in a timely manner, then adopters may opt for 
traditional samples as a matter of convenience or even necessity. Finally, the most common 
threat identified in the literature around DBS use is regulatory uncertainty [14, 36]. At 
present, federal and international guidelines around DBS are lacking in comparison with 
traditional samples [27, 45]. The absence of clear regulatory guidance, and the potential 
for new or unexpected regulations will continue to constrain widespread DBS adoption 





With nearly 2,000 analytes measured in more than 150 different analytic methods, DBS 
presents potential adopters with a wide range of options for application. In the basic 
sciences, analytes measured in DBS have been published across the spectrum of ‘omics-
based analyses, including the genome, epigenome, transcriptome, proteome, and 
metabolome [13, 25, 34]. Beyond basic science, DBS has been applied in the field for use 
in public health and medicine for measuring markers of exposure (e.g. pathogens, 
environmental toxicants), physiological response, and health outcomes [5, 7, 33, 49]. From 
diagnosis to surveillance to retrospective study, the repertoire of DBS application continues 
to expand. 
 
A majority of analytes measured in DBS and extracted for inclusion in the DBS database 
are classified as ‘Small Molecule’ and nearly two thirds of unique analyte/analytic method 
combinations in the database were measured by methods classified broadly as ‘Mass 
Spectrometry’ (Figure 2-4). These findings are not unexpected given the requirement of 
highly sensitive analytic instrumentation such as MS for measuring small quantity 
biosamples, and the wide range of analytes that can be measured in a single analytic run 
with MS methods. Though slightly less common, a range of large molecules have also been 
measured in DBS and can be found in the database, including therapeutic proteins, 
monoclonal antibodies, and a variety of carbohydrates among others (Table 2-3).  
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DBS for measuring nucleic acids (i.e., DNA and RNA), though much less common in the 
database than small or large molecule analytes, have been no less effective in their 
application. DNA has been demonstrated to be stable in DBS for more than 10 years, and 
RNA, while traditionally unstable in liquid samples, has shown remarkable stability in 
DBS [22, 66]. The stability of RNA in dried blood spots is a direct consequence of the 
absence of water in a dried matrix, as water is required for RNase action to degrade RNA 
[83]. Similar improvements in stability for analytes susceptible to hydrolysis suggests that 
DBS is not just an adequate replacement for plasma or serum, but in some instances, it may 
be a preferred matrix. 
 
An examination of the range of analytic methods that have been applied to DBS confirm 
the theory that dried blood spots can, in principle, be applied to measuring anything you 
typically measure in liquid whole blood, plasma, or serum. Furthermore, our analyte 
database demonstrates an often-cited strength of DBS, that it can be applied to most 
common analytic instruments. In fact, analytes in the database have been measured with 
all the most common analytic methods. Still, the application of DBS in the literature and 
the rigor of validation methods applied are variable [20, 24, 27]. Potential adopters may 
consider the analyte database as a means for determining if DBS is a possible solution to 
their respective needs, but additional inspection of the specific analytes of interest and their 
validation of assay studies will be required prior to adoption. Original research for analytes 
measured in DBS can be found in the analyte database and may serve as a good first step 
for those considering adoption. 
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We have identified two potential limitations in our efforts to build a comprehensive analyte 
database for DBS. First, while our methods cast a wide net in terms of search strategies, 
we limited our study to three primary databases. Relevant publications not included within 
these databases would not have been captured by our review. However, we selected our 
databases in consultation with the medical librarian and after preliminary searches of other 
potential databases returned mostly duplicates and/or few relevant studies. Second, the size 
and comprehensiveness of the review required nearly 12 months to complete. Relevant 
studies published during the months between our final search and publication would not be 
captured in our review. We believe this is a common limitation of most review papers, and 
is an acceptable limitation of our study given the scope of our review. 
 
SWOT Analysis 
The combined strengths of DBS allow for removal of two often limiting components of 
traditional liquid samples: phlebotomy and cold chain handling [30]. This removal makes 
DBS a suitable alternative to traditional matrices for sampling outside of the clinic or lab, 
which allows DBS to be used in a range of settings [24]. DBS lends itself to sampling in 
situations as simple as the home or as complex as large longitudinal study designs in austere 
environments [5]. The use of simple to collect, minimally invasive, small volume samples 
like DBS also provide substantial benefit in the reduction and refinement in the use of 
animal subjects across the sciences [18, 35]. These same benefits allow DBS to improve 
sampling from hard-to-reach or otherwise vulnerable populations as well as problematic 
groups such as neonates and the elderly where large volumes of blood collected by 
venipuncture can be difficult [32, 34]. In addition to the advantages of DBS for sampling 
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in particularly problematic environments, improved stability for some analytes, such as 
RNA and other analytes susceptible to degradation due to hydrolysis, make DBS not just 
more suited than traditional samples to some environments, but more suited to entire 
classes of analytes as well [29, 53]. The strengths of DBS, therefore, make a compelling 
case for potential adopters.  
 
The weaknesses involved with DBS sampling cannot be ignored, but may be better 
understood by potential adopters by considering them in the context of their opportunities. 
For example, limitations in the retention and detection of VOCs could be obviated by 
identification of relevant downstream metabolites [7]. Additionally, issues in limits of 
detection for small volume samples have largely been addressed through advancements in 
the quality and availability of highly sensitive analytical instrumentation [35]. Still, even 
when measured precisely, the variability inherent to dried microsamples stored under 
ambient conditions remains an impediment to wider adoption.  
 
Current approaches to DBS rely on conversion of measurements for single analytes to 
corresponding plasma or serum values for the purposes of applying a clinically relevant 
diagnostic range to an individual analyte. However, as a nontraditional sample matrix, the 
differences between DBS and plasma or serum are substantial, and each present the 
possibility of introducing bias into converted measurements. What’s more, even minimal 




Alternatively, some of the variability in DBS measurements has been resolved by use of 
direct measurements rather than conversions to plasma or serum values, and through 
application of diagnostics that apply molar ratios, or relative values for multiple analytes, 
rather than single analyte ranges [10, 42]. This approach has been applied in newborn 
screening for PKU and has demonstrated improvements in diagnostic performance [10]. It 
may be the case that clinical application of DBS is better served by developing diagnostic 
criteria that are especially suited to DBS rather than attempting to apply DBS 
measurements to diagnostics originally developed for traditional plasma or serum. 
However, such an approach requires further investigation.  
 
Another concern around DBS adoption is lack of consistency in methods for published 
validation studies; however, as recommendations for DBS validation have been recently 
put forth, and as regulatory agencies consider adoption of validation guidelines, the quality 
and availability of validation studies for DBS should improve [40, 45, 67-68]. In the 
meantime, potential adopters should become familiar with the parameters of a quality DBS 
bioanalytic validation [27, 55, 63]. Potential adopters must also remain aware of the 
regulatory landscape, which at present is poorly defined for DBS [45, 74]. However, as 
interest and use in the technology has expanded, scientific organizations as well as industry 
and regulatory agencies, have begun to take notice. For example, having recognized the 
need for greater collaboration and pooling of resources, the European Bioanalysis Forum 
created the Microsampling Topic Team, and the Global Bioanalysis Consortium recently 
began investigations specifically into DBS [59].  
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Though FDA in the US, and other regulatory agencies, do not yet accept DBS as a 
standalone sampling matrix for drug studies and most clinical applications, they have 
encouraged adopters to work closely with regulatory agencies while conducting bridging 
studies between traditional samples and DBS [74]. In the near term, these studies will 
undoubtedly add costs and complexity in adoption, but will be less necessary as more are 
completed and regulatory agencies grow more familiar with DBS application. 
 
The advantages of DBS in terms of sampling from neonates or in austere environments, 
and their use in biobanking and retrospective investigation may also present one of the 
biggest threats to adoption [7, 44, 50, 52]. Consideration must be given to the feasibility 
and appropriateness of analyzing DBS samples collected from neonates or from persons in 
low resource for purposes other than they were originally intended. Though this could be 
resolved by a more expansive consenting process, questions around whether a person can 
truly consent for things neither they nor the person consenting them have yet considered 
need to be addressed. More restrictive use of residual samples could also be an effective 
measure for protecting against this threat, but would limit the utility of DBS samples for 
longitudinal and retrospective investigations. 
 
Conclusion 
DBS provide a wide range of existing and potential applications that extend beyond the 
reach of traditional samples. The utility of DBS for collection of blood outside of the clinic 
provide a range of possible applications from the research lab to the home to the most 
remote environments on earth. Current limitations though serious, are not intractable. 
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Issues of variability in measurements from DBS use in public health and medicine can be 
addressed by a variety of existing and emerging innovations. Technological advancements 
in material inputs for DBS and data analytic approaches for measurement have, and will 





















TABLES AND FIGURES 
 
Table 2-1. Summary of review search terms, limiters, databases, inclusion and 
exclusion criteria. 
Search Terms A combination of controlled vocabulary and keyword terms were used to 
represent the two main concepts of DBS and validation studies. Terms 
used included: dried blood spot testing, blood spot, dried blood, guthrie, 
blood sampling paper, filter paper blotter, filter paper disk, dried filter 
paper, PKU card, blood collection card, validation studies, evaluation 
studies, validation 
Search Limiters Language: None 
Publication Date: None 
Databases PubMed, Embase, SciFinder 
Inclusion Criteria 1. A review paper, commentary or short report 
2. Discusses a category or domain of DBS (e.g. DBS in clinical 
trials, DBS methods development, etc.) 
3. Involves human subjects or animals subjects with explicitly 
stated relevance to human health (e.g. animal toxicology or 
pharmacology studies) 
Exclusion Criteria 1. DBS is not a focus of the study (i.e., DBS is not explicitly 
mentioned as relevant to the stated purpose, objective, or aims of 
the review) 












Table 2-2. Summary table of included studies. 
Author & 





The application of dried 
blood spot sampling in 
global clinical trials. 
DBS adoption in clinical trials will likely see 
substantial savings in cost and improvements 




experience of incurred 
sample reanalysis for dried 
blood spot samples. 
The future of DBS in drug studies is 
dependent upon solving issues of hematocrit 
effect and building confidence in DBS use in 
industry through good quality data. 
Bowen 2014 
[3] Review 
Challenges and Experiences 
with Dried Blood Spot 
Technology for Method 
Development and 
Validation. 
New techniques in DBS are emerging, but 
more validation and vetting are required. 
Though challenges remain, in some 




Investigations into the 
environmental conditions 
experienced during ambient 
sample transport: impact to 
dried blood spot sample 
shipments. 
Data loggers are a feasible method for 
tracking environmental conditions in samples 
during transport and storage. DBS samples 
transported without controlled environments 
are likely to experience extreme conditions, 
especially in flight.  
Brindle 2014 
[5] Review 
Applications of Dried Blood 
Spots in General Human 
Health Studies. 
DBS are a well suited biological matrix for 
human health studies, and their convenience 
enable adoption in a variety of field settings. 
Burnett 2011 
[6] Review 
Dried blood spot sampling: 
practical considerations and 
recommendation for use 
with preclinical studies. 
DBS use in preclinical studies can provide 
substantial benefits towards principles of the 
3Rs (reduction, refinement, replacement).  
Calafat 2014 
[7] Review 
Applications of dried blood 
spots in environmental 
population studies 
DBS use allows biomonitoring in vulnerable 
and otherwise difficult to sample 
populations, however, limited data is 
available on DBS use for biomonitoring. 
Validated protocols for DBS use and further 
research to the suitability of DBS for epi 
studies are needed. 
Chace 2003 
[8] Review 
Use of tandem mass 
spectrometry for 
multianalyte screening of 
dried blood specimens from 
newborns. 
MS/MS technologies are suitable for 
newborn screening and other mass screening 
programs. MS/MS improves detection of 
many diseases and may expand diagnostics 
to other important disorders in pediatric 
medicine. 
Chace 2014a 
[9]  Review 
The Use of Dried Blood 
Spots and Stains in Forensic 
Science. 
DBS provide a several benefits for use in 
forensic science, especially in the ability to 
collect samples closer to the time of an event. 
However, small sample volumes remain a 
limitation for measuring some drugs. 
Chace 2014b 
[10] Review 
Applications of Dried Blood 
Spots in Newborn and 
Metabolic Screening. 
DBS analysis for newborn screening has 
helped to improve the lives of children and 
opened new opportunities in clinical 






A powerful couple in the 
future of clinical 
biochemistry: in situ 
analysis of dried blood spots 
by ambient mass 
spectrometry. 
Current techniques in ambient ionization 
coupled with MS have enabled direct 
desorption/ionization of molecules from 
solid samples, such as DBS. It is likely that 
ambient MS methods will be increasingly 




Dry blood spot technique: a 
review 
Though DBS is the dominant sample matrix 
for newborn screening and has proved 
convenient for therapeutic drug monitoring, 
due to limitations in sample volume and 
assay sensitivity, it is unlikely to fully 
replace traditional whole blood, plasma or 




Direct analysis of dried 
blood spots coupled with 
mass spectrometry: concepts 
and biomedical applications. 
Recent advancements in direct MS/MS 
analysis of DBS samples offer competitive 
alternatives for high throughput and 
sensitivity compared with traditional plasma 
samples. Commercialization of automation 
methods in direct MS/MS for DBS indicate 
growing maturity of the technology.  




Current strategies for coping 
with the hematocrit problem 
in dried blood spot analysis. 
Several strategies for resolving issues of 
hematocrit have been developed, however, 
challenges remain. Differences between 
capillary and venous blood samples will 
continue to present a challenge to DBS even 
if issues of hematocrit are completely 
resolved. 
De Kesel 2013 
[15] Review 
Hemato-critical issues in 
quantitative analysis of 
dried blood spots: 
challenges and solutions. 
DBS offer several advantages over 
traditional liquid samples, but despite these 
advantages, DBS still face substantial 
challenges. The issue of hematocrit effect 
remains a serious concern, however, multiple 
methods developed for dealing with 




Dried blood spots: analysis 
and applications. 
Due to reductions in the cost and availability 
of technology, DBS use will continue to 
expand from health monitoring to rapid 
diagnostics to drug development and 





Bioanalysis Zone: DBS 
survey results. 
At present, DBS use is more appropriate as a 
supplement than a replacement to plasma for 
pharmacokinetic studies. However, DBS 
may have a niche for studies with limited 
blood volume requirements (e.g. pediatrics) 
or in low resource settings where traditional 
sampling is not feasible.. 
Desai 2013 
[18] Review 
Dried blood spot sampling 
analysis: recent advances 
and applications 
DBS use in clinical trials will likely result in 
substantial savings in costs as well as overall 
improvements in data quality.  
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Dezateux 
1998 [19] Review 
Evaluating newborn 
screening programmes 
based on dried blood spots: 
future challenges. 
Due to advancements in technology such as 
MS/MS, newborn screening applications are 
expanding. However, such expansion should 
be based on unbiased benefits vs. harm 
estimates, which cannot be obtained solely 
by observational study.   
Edelbroek 
2009 [20] Review 
Dried blood spot methods in 
therapeutic drug monitoring: 
methods, assays, and 
pitfalls. 
DBS has been applied for a range of 
medicines in therapeutic drug monitoring, 
but the benefits of DBS must be measured 
against potential errors due to sampling 
materials and methods. Standardization 






considerations as to when to 
use dried blood spot 
sampling. 
While DBS is a suitable matrix for 
pharmacokinetic studies, issues around 
blood: plasma ratio, hematocrit, and other 
physicochemical properties should be 
considered before DBS is adopted. 
Hannon 2014 
[22] Review 
Overview of the history and 
applications of dried blood 
samples. 
DBS have a long history of use and are today 
in widespread use. Going forward, 
advancements in filter paper matrices and lab 
instrumentation are likely to improve the 




Microsample analyses via 
DBS: challenges and 
opportunities. 
DBS have several advantages over traditional 
samples. Advancements in polymer 
membranes and other substrate materials for 
filter paper cards will likely improve 
measurements derived from DBS samples; 
however, the current regulatory landscape 
will continue to hinder DBS adoption. 
Hofman 2015 
[24] Review 
Role of therapeutic drug 
monitoring in pulmonary 
infections: use and potential 
for expanded use of dried 
blood spot samples. 
DBS is a promising method for improving 
therapeutic drug monitoring for pulmonary 
infections, especially for some drug classes; 
however, validation work remains to be 
done.  
Ignjatovic 
2014 [25] Review 
The utility of dried blood 
spots for proteomic studies: 
Looking forward to looking 
back. 
Though DBS has already been effectively 
applied to epigenetic-based studies, it is 
important to develop improved technologies 
for DBS application in protein-based studies, 





in Dried Blood Spot 
Analysis. 
Due to the benefits associated with DBS 
sampling, the technique has already proven 
useful for a range of applications. The use of 
derivatization techniques, however, may be 
necessary to effectively apply DBS 
measurements. As automation increases, 
direct derivatization approaches are likely to 
gain importance in the future.  
Jager 2014 
[27] Review 
Procedures and practices for 
the validation of 
Large differences exist in DBS validations 
conducted over the past decade. While DBS 
has several parameters above and beyond 
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bioanalytical methods using 
dried blood spots: a review. 
traditional samples, 40% of the published 
literature lack a single DBS-specific 
validation parameter. 
Ji 2012 [28] Review 
What is next for dried blood 
spots? 
Due to the scientific, social, ethical, and 
financial constraints of drug research, 
microsampling with ambient storage in dried 
matrices will be needed. Such adoption will 
require better understanding of plasma versus 
blood concentrations as well as innovations 
in technology. 
Ji 2014 [29] Review 
Potential Role for Dried 
Blood Spot Sampling and 
Bioanalysis in Preclinical 
Studies. 
As efforts to resolve current issues in DBS 
analysis continue to expand, DBS is likely to 
be well positioned to be the future matrix for 
nonclinical and clinical studies, though 




Application of Enzyme 
Immunoassay Methods 
Using Dried Blood Spot 
Specimens. 
DBS analysis through ELISA have been 
extensively evaluated and have been 
demonstrated to be effective for a range of 
biomarkers. Though constraints remain, 
limitations in DBS can be overcome by 
optimization and validation procedures prior 
to application in the field. 
Keevil 2011 
[31] Review 
The analysis of dried blood 
spot samples using liquid 
chromatography tandem 
mass spectrometry. 
Combining LC-MS/MS with DBS can 
improve analyte stability and specificity, and 
could provide a powerful tool for future 
clinical research and application. 
Kulmatycki 
2014 [32] Review 
Application of Dried Blood 
Spot Sampling in Clinical 
Pharmacology Trials and 
Therapeutic Drug 
Monitoring. 
DBS has become an established method for 
sampling aimed at therapeutic drug 
monitoring in developing countries. The 
method is particularly useful for special 
populations, such as pediatrics. DBS use in 
these settings can help improve personalized 
exposure-response strategies for patients. 
Lakshmy 2014 
[33] Review 
Role of dried blood spots in 
health and disease diagnosis 
in older adults. 
DBS affords several advantages over 
traditional sampling methods, especially for 
older populations. Many of the current 
limitations in DBS can be overcome by 
advancements in technology for 
measurement and automation. 
Lehmann 
2013 [34] Review 
Current and future use of 
“dried blood spot” analyses 
in clinical chemistry. 
DBS has advantages over traditional matrices 
in terms of sampling, transportation, storage, 
and biosafety. As a consequence, DBS is 
particularly advantageous for self-sampling 
at home. Innovations in microfluidics, 
multiplex systems, MS, and automation will 




Dried blood spot (DBS) 
sampling technique and its 
applications. 
Due to recent advancements in analytical 
instrumentation, such as LC-MS/MS, DBS is 
gaining wider attention and adoption in 
preclinical and population-based studies. 
 50 
However, issues of sensitivity and sample 
homogeneity remain. Further instrument and 
method development may help resolve these 
issues and speed adoption. 
Li 2012 [36] 
Commentary/
Short Report 
Will 'green' aspects of dried 
blood spot sampling 
accelerate its 
implementation and 
acceptance in the 
pharmaceutical industry?. 
DBS technology affords several advantages 
over traditional samples in terms of 
reductions in material inputs and wastes. 
These advantages are likely to accelerate 
adoption by the pharmaceutical industry if 
data generated by DBS studies prove 
reliable. 
Liu 2014 [37] Review 
Paper Spray Ionization for 
Direct Analysis of Dried 
Blood Spots. 
Paper spray ionization provides a simple, 
rapid, and sensitive method for direct 
analysis of DBS. 
Li 2014 [38] Review 
Considerations in 
Development and 
Validation of LC‐MS/MS 
Method for Quantitative 
Analysis of Small 
Molecules in Dried Blood 
Spot Samples. 
Due to the benefits of DBS, the technology is 
currently being explored as a sampling tool 
in bioanalytics. In order for DBS to achieve 
wider acceptance, issues of reliability in 
achieving accurate and reproducible results 
must be resolved.  
Li 2010 [39] Review 
Dried blood spot sampling 
in combination with LC‐
MS/MS for quantitative 
analysis of small molecules. 
DBS-LC-MS/MS for quantitative analysis of 
small molecules has emerged as an important 
tool, however issues of assay sensitivity due 
to small sample volume remain. 
Improvements in DBS cards and their 
bioanalysis are needed. 
Majors 2011 
[40] Review 
New directions in whole 
blood analysis: dried blood 
spot analysis and beyond. 
DBS has several advantages over plasma or 
serum for drug discovery and development 
studies. The advantages of DBS for the 
pharmaceutical industry are likely to drive 





opportunities in mass 
spectrometric analysis of 
proteins from dried blood 
spots. 
Though traditional used for metabolite and 
small molecular analysis, DBS are a potential 
source of protein biomarkers. As methods for 
proteomic analyses of DBS continue to 
emerge, DBS may replace plasma as the 
sample of choice. 
Mauch 2012 
[42] Review 
Automation of DBS 
sampling for 
biopharmaceutical analysis. 
DBS has a variety of benefits for 
pharmaceutical bioanalysis. Several systems 
for automating DBS analysis are currently 
available and have thus far focused on card 
handling, avoidance of carry-over, 
robustness of analysis, and traceability for 
workflow, all of which are required for DBS 




Development and validation 
of assay protocols for use 
with dried blood spot 
samples. 
DBS are a “field-friendly” method of 
biosample collection and can help bridge the 
gap between field-level survey data and 
biological mechanisms. However, 
 51 
convenience in the field must be balanced 
against challenges of quantification in the 
lab, which still requires more work in assay 
development and validation. 
McDade 2007 
[44] Review 
What a drop can do: dried 
blood spots as a minimally 
invasive method for 
integrating biomarkers into 
population-based research. 
DBS provide a field-ready tool for 
interdisciplinary research by allowing for 
social/behavioral data to be combined with 
biological data. However, the advantages of 
DBS use must be considered in the context 
of their added burden, however minimal, on 
researchers in the field. 
Meesters 2013 
[45] Review 
State-of-the-art dried blood 
spot analysis: an overview 
of recent advances and 
future trends. 
DBS is still developing from a time and labor 
intensive technique to a sophisticated highly 
quantitative and reliable method for 
quantification of analytes in microsamples. 
Though advancements in DBS methods have 
spurred adoption in the life sciences, hurdles 
remain and must be overcome for wider 
adoption. 
Mei 2014 [46] Review 
Dried blood spot sample 
collection, storage, and 
transportation. 
As filter paper technology and analytical 
methods have improved, DBS use in 
biochemical and molecular testing has 
expanded. If collected, processed, and stored 
appropriately, DBS use in newborn screening 
can ensure timely and accurate results, less 
stress to infants and families, and decrease 
the overall burden on the health system. 
Mei 2001 [47] Review 
Use of filter paper for the 
collection and analysis of 
human whole blood 
specimens. 
CDC’s NSQAP plays an important role in 
quality assurance for DBS in newborn 
screening, and also provide a vital resource 
for others considering application of new 
analytic methods to filter paper. 
Nageswara 




improving dried blood spot 
analysis. 
LC-MS for DBS provides a rapid and high-
through analysis tool, which could solve 
many of the issues around online extraction, 
high-throughput, sensitivity, and selectivity. 
Though LC-MS/MS is expected to play an 
important role in the future, further 
improvements will be required to achieve 
full automation and ultra-high performance. 
Parker 1999 
[49] Review 
The use of the dried blood 
spot sample in 
epidemiological studies. 
DBS has advantages over other 
microsamples such as saliva and urine, and is 
particularly suited to surveillance uses in low 




studies in children: a new 
use of dried blood spots. 
DBS has demonstrated a degree of accuracy 
and precision comparable to that of 
traditional samples. Use of high sensitive 
detection systems with DBS may enabled 
their use in PK studies with children, as well 
as several other important applications like 




New technologies extend 
the scope of newborn blood‐
spot screening, but old 
problems remain 
unresolved. 
New analytical technique and treatment 
methods have expanded newborn blood-spot 
screening, however, there are concerns that 
existing programs are being driven by 
analytical performance rather than clinical 
need. Furthermore, screening policies 
currently vary greatly between countries. 
Politt 2009 
[52] Review 
Newborn blood spot 
screening: New 
opportunities, old problems. 
Newborn screening methods are evolving 
quickly and coverage is expanding. 
Screening programs vary greatly within and 
between countries. There is a need for 
evidence-based decisions around which 
diseases to include in screening as 
technology has enabled a wide-range of 
screening possibilities, but many may be 
inconsistent with clinical priorities. 
Quraishi 2013 
[53] Review 
The use of dried blood spot 
samples in screening drugs 
of abuse. 
DBS application for detection of drugs of 
abuse has potential, but use must be 
measured against potential for error within 
the method. Quality of sampling paper, 
standardization, and sensitivity of analytic 
methods are critical factors in achieving 
reliable results from DBS. 
Sadones 2014 
[54] Review 
Spot them in the spot: 
analysis of abused 
substances using dried blood 
spots. 
DBS methods are currently available for the 
detection of a wide range of drugs of abuse. 
A majority of these methods have 
demonstrated sufficient sensitivity for 
forensic applications, however, more 
experiments are required for implementation 
of DBS in routine analysis. 
Sharma 2014 
[55] Review 
Dried blood spots: concepts, 
present status, and future 
perspectives in bioanalysis. 
Advanced in analytical tools combined with 
financial and ethical benefits make DBS a 
suitable sampling method for a range of 
applications. Though limitations remain, 
advantages in sample collection, storage, and 
shipment make DBS a preferred technique, 
however, regulatory issues and 
advancements in automation will be 
necessary for wider adoption for drug 
discovery.  
Shi 2011 [56] 
Commentary/
Short Report 
Assay dynamic range for 
DBS: battles on two fronts. 
Enhancements in LC-MS/MS methods have 
helped to improve the dynamic range of DBS 
assays, however, issues involving dilution 
remain a constraint.  
Smit 2014 
[57] Review 
An overview of the clinical 
use of filter paper in the 
diagnosis of tropical 
diseases. 
DBS have demonstrated sensitivities and 
specificities comparable to gold standard 
methods; however, DBS has not consistently 
been used effectively due to a lack of 
standardized methodologies. DBS may prove 
to be an effective tool for empowering 
healthcare workers with improved lab-based 
diagnostics, but additional research and 
validation will be required. 
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Snijdewind 
2012 [58] Review 
Current and future 
applications of dried blood 
spots in viral disease 
management. 
DBS offers opportunities for diagnostics and 
treatment around viral disease. However, 
these opportunities require application of 
uniform and robust protocols along with 
defined treatment and interventions at the 





A dried blood spot update: 
still an important 
bioanalytical technique?. 
Despite challenge of hematocrit and spot 
homogeneity, DBS offers substantial benefits 
for sampling in some study types, 
particularly those involving pediatric 
patients, therapeutic drug monitoring, or 
sampling in remote locations. 
Stove 2012 
[60] Review 
Dried blood spots in 
toxicology: from the cradle 
to the grave?. 
DBS sampling has been effectively used for 
toxicological purposes from birth through 
autopsy. Issues of contamination, hematocrit, 
spot volume, and site of punching remain, 
however, advancements in automation and 




A brief review on dried 
blood spots applications in 
drug development 
Simplicity of sampling in combination with 
financial and ethical benefits have led to 
DBS adoption in drug development. These 
advantages compared with traditional plasma 
will likely ensure DBS remains an 




Clinical Implications of 
Dried Blood Spot Assays 
for Biotherapeutics. 
DBS has demonstrated to be an accurate and 
precise method for quantification of 
biotherapeutics. Additionally, some analytes 
such as peptides and proteins may even be 
more stable in DBS compared with plasma. 
Still, issues of hematocrit must still be 
resolved before DBS can be more widely 
adopted in PK and TK studies. 
Taneja 2013 
[63] Review 
Dried blood spots in 
bioanalysis of antimalarials: 
relevance and challenges in 
quantitative assessment of 
antimalarial drugs. 
DBS is well suited to studies involving 
antimalarial drugs, but issues remain. 
Additional tests will be required in order to 
validate DBS for these purposes, and issues 
of card type, spot size, blood volume spotted, 
hematocrit, matrix effects, and 




Analytical methods used in 
conjunction with dried 
blood spots. 
DBS have been applied with a wide range of 
different analytic methods, including 
newborn screening, drug discovery and 
development, and HIV studies in resource 
limited settings among others. Issues of 
quality assurance for filter paper, hematocrit 
effects, and proper protocol for drying, 
storage, and transport are essential to 
effective application of the technology. 
Going forward, advancements in automation 
paired with highly sensitive instruments will 
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quantitative analysis of 
DBS: can it shift the balance 
in over-burdened healthcare 
systems?. 
As populations continue to age, self sampling 
with DBS for quantitative analysis provides a 
valuable tool for shifting the balance and 
burdens in healthcare away from traditional 
hospitals and clinics, and thereby reducing 
pressure on acute care services, while 




Dried blood spot analysis to 
assess medication adherence 
and to inform 
personalization of treatment. 
There is a paucity of research around DBS 
use for medication adherence, however, the 
opportunity to personalize health services 
through measuring adherence to treatment 






Update of the EBF 
recommendation for the use 
of DBS in regulated 
bioanalysis integrating the 
conclusions from the EBF 
DBS-microsampling 
consortium. 
DBS is considered a developing technology 
and further innovation and improvements 
will be required to provide more balance 
between existing advantages and limitations. 
DBS is not yet viewed as a general 
alternative to traditional liquid samples, 
however, when appropriate applied, DBS 






EBF recommendation on the 
validation of bioanalytical 
methods for dried blood 
spots. 
DBS require several adaptations, 
enhancements and revisions to current 
validation methods in order to appropriately 
validate an assay for DBS. As interest in the 
technology increases it is important that 








The ability of DBS to mimic existing 
traditional samples will be essential to its 
adoption. Regulatory approval of DBS is 
likely to remain a case-by-case situation 
whereby the quality and robustness of the 
data will be critical.  
Wilcken 2012 
[70] Review 
Screening for disease in the 
newborn: the evidence base 
for blood-spot screening. 
MS/MS with DBS in newborn screening 
have been demonstrated to be effective for a 
range of disorders, however, concerns around 
anxiety due to screening, false positives, 
adverse effects of unwarranted treatments for 
mild variants and others remain a concern. 
Selection of diseases to include in screening 
would be more effective with full integration 





monitoring by dried blood 
spot: progress to date and 
future directions. 
DBS has been used increasingly in 
therapeutic drug monitoring and methods 
have been applied effectively for dealing 
with the influence of hematocrit. However, 
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Punching and Extraction 
Techniques for Dried Blood 
Spot Sample Analysis. 
Punching and extraction methods for DBS 
are critical steps to effective application of 
the technology. Furthermore, investigation 
and understanding of the physicochemical 
properties of target analytes is essential to 





Increasing efficiency for 
dried blood spot analysis: 
prospects for automation 
and simplified sample 
analysis. 
Advantages of DBS for preclinical and 
clinical studies includes a marked reduction 
in blood volume requirements and simplified 
sampling logistics. At present, approaches 
are not adequate for large numbers of 
samples and improvements in efficiency are 
necessary for the benefits of DBS to be fully 
realized. 
Xu 2013 [74] Review 
Merck's perspective on the 
implementation of dried 
blood spot technology in 
clinical drug development-
why, when and how. 
DBS use in PK studies requires 
understanding of several parameters, 
including blood-to-plasma ratio, hematocrit, 
plasma unbound fraction, and blood cell 
partition. When considering adoption, quick 
feasibility studies should be conducted. At 
present, bridging studies will be required 
before DBS can be applied as a stand alone 
sample matrix, and regulatory feedback is 
recommended on a case-by-case basis. 
Zhang 2013 
[75] Review 
Best Practices in LC‐MS 
Method Development and 
Validation for Dried Blood 
Spots. 
Due to the many benefits of the technology, 
DBS is increasingly being considered as a 
sampling tool in bioanalytics. However, 
issues of reliability in providing accurate and 
reproducible results must be resolved before 
wider adoption can occur. As the technology 
advances, efforts must be made to resolve 
challenges of hematocrit effects, spot 
homogeneity, extraction recovery, analyte 

















Table 2-3. Comprehensive list of analytes identified in the literature to have been measured 
in dried blood spots.  
SMALL MOLECULE 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































14‐3‐3 Protein beta/alpha 
14‐3‐3 Protein theta 
14‐3‐3 Protein zeta/delta 

















































AMG 162 (therapeutic 
monoclonal antibody) 
AMG 517 (therapeutic 
monoclonal antibody) 
AMG A (therapeutic 
monoclonal antibody) 
































B‐cell activitating factor 
Babesia microti antibody 























C‐C motif chemokine 19 
C‐C motif chemokine 21 
C‐C motif chemokine 24 
C‐peptide 
C‐reactive protein 
C‐X‐C motif chemokine 10 
C‐X‐C motif chemokine 11 
C‐X‐C motif chemokine 13 
C‐X‐C motif chemokine 5 
C‐X‐C motif chemokine 9 
C1 Inactin 
C3B Inhibitor 





Calpain small subunit 1 
Calpastatin 
Campylobacter antibody 
Cancer antigen 125 
Carbonic anhydrase 1 
Carbonic anhydrase 2 
Carbonic anhydrase 3 









Chemokine (C‐C motif) 
ligand 2 
Chemokine (C‐C motif) 
ligand 3 
Chemokine (C‐C motif) 
ligand 4 
Chemokine (C‐C motif) 
ligand 5 
Chemokine (C‐C motif) 
ligand 8 







channel protein 1 
Cholinesterase 
Chylomicron 
Cluster of differentiation 3 
Cluster of differentiation 3 
zeta antibody 
Cluster of differentiation 4 
Clusterin 
Coagulation factor XIIa 
heavy chain 
Coagulation factor XIII A 
chain 
Cofilin‐1 



















C4 beta chain 
Complement component 




C8 beta chain 
Complement component 
C9 
Complement factor 1 
Complement factor B 
COP9 signalosome complex 
subunit 3 
Coxiella burnetii antibody 
Creatine kinase 
Creatine kinase B‐type 

























Early activation antigen 









Epidermal growth factor 





Epithelial cell adhesion 
molecule 
Epstein‐Barr virus antibody 
Erythrocyte 
acetylcholinesterase 
Erythrocyte band 7 integral 
membrane protein 
Erythrocyte membrane 





initiation factor 5A‐1 
Extracellular matrix 
metalloproteinase inducer 
F‐actin capping protein 
subunit beta 
F‐box only protein 7 
Factor H 
Factor V Leiden 
Fas antigen ligand 
Fasciola hepatica antibody 





Fibrinogen alpha chain 
Fibrinogen beta chain 
Fibrinogen gamma chain 
Fibroblast growth factor 2 
Fibronectin 




kinase 3 ligand 























Giardia lamblia antibody 






















stimulating factor  
Granulocyte‐macrophage 
colony‐stimulating factor 
Green fluorescent protein 




Heat shock 70 kDa protein 
1 
Heat shock 70 kDa protein 
2 
Heat shock 70 kDa protein 
8 
Heat shock protein 27 
Heat shock protein 90 
Helicobacter pylori 
antibody 










Hemoglobin O Arab 
Hemoglobin S 
Hemoglobin subunit alpha 
Hemoglobin subunit delta 
Hemoglobin subunit 
gamma‐1  
Hemoglobin subunit zeta 
Hemopexin 
Hemozoin 
Heparin cofactor 2 
Heparin‐binding EGF‐like 
growth factor 
Hepatitis A virus antibody 
Hepatitis B virus core 
antibody 
Hepatitis B virus core 
antigen maternal antibody 
Hepatitis B virus envelope 
antibody 
Hepatitis B virus envelope 
antigen 
Hepatitis B virus surface 
antibody 
Hepatitis B virus surface 
antigen 
Hepatitis C virus antibody 
Hepatitis C virus antigen 
Hepatitis C virus core 
antigen 
Hepatocyte growth factor 
Hepatocyte growth factor 
receptor 
Herpes simplex virus 2 
antibody 




Histone H2A type 1‐H 
HIV antibody 
HIV p24 antigen 
HIV‐1 antibody 
HIV‐1 envelope peptide 








Human T‐Cell lymphotropic 
virus type 1 antibody 
Human T‐Cell lymphotropic 














chain C region 
Immunoglobulin gamma‐2 
chain C region 
Immunoglobulin gamma‐3 
chain C region 
Immunoglobulin gamma‐4 
chain C region 
Immunoglobulin heavy 
chain V‐1 region EU 
Immunoglobulin heavy 
chain V‐III region CAM 
Immunoglobulin heavy 
chain V‐III region GA 
Immunoglobulin heavy 
chain V‐III region GAL 
Immunoglobulin heavy 
chain V‐III region TEI 
Immunoglobulin heavy 
chain V‐III region TIL 
Immunoglobulin heavy 
chain V‐III region TRO 
Immunoglobulin heavy 
chain V‐III region WEA 
Immunoglobulin J chain 
Immunoglobulin kappa 
chain C region 
Immunoglobulin kappa 
chain V‐I region CAR 
Immunoglobulin kappa 
chain V‐I region DEE 
Immunoglobulin kappa 
chain V‐I region Lay 
Immunoglobulin kappa 
chain V‐I region Mev‐like 
Immunoglobulin kappa 
chain V‐I region Ni 
Immunoglobulin kappa 
chain V‐II region MIL 
Immunoglobulin kappa 
chain V‐II region RPMI 
6410 
Immunoglobulin kappa 
chain V‐III region B6 
Immunoglobulin kappa 
chain V‐III region HAH 
Immunoglobulin kappa 
chain V‐III region LOI 
Immunoglobulin kappa 
chain V‐III region SIE 
Immunoglobulin kappa 
chain V‐III region VG 
(fragment) 
Immunoglobulin kappa 
chain V‐III region VH 
(fragment) 
Immunoglobulin kappa 
chain V‐IV region 
(fragment) 
Immunoglobulin kappa 
chain V‐IV region Len 
Immunoglobulin lambda 
chain V‐I region HA 
Immunoglobulin lambda 
chain V‐I region WAH 
Immunoglobulin lambda 
chain V‐III region LOI 
Immunoglobulin lambda 
chain V‐III region SH 
Immunoglobulin lambda 
chain V‐IV region Hil 
Immunoglobulin lambda 
chain V‐IV region MOL 
Immunoglobulin lambda‐1 
chain C region 
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Immunoglobulin lambda‐2 
chain C region 
Immunoglobulin lambda‐7 
chain C region 
Immunoglobulin lamda 
chain V region 4A 
Immunoglobulin M 
Immunoglobulin mu chain 
C region 
Immunoglobulin mu heavy 
chain disease protein 
Immunoglonin gamma‐3 




Importin subunit beta‐1 
Influenza A pdm09 virus 
antibody 
Insulin 
Insulin‐like growth factor 1 
Insulin‐like growth factor 
binding protein 1 
Insulin‐like growth factor 
binding protein 2 
Insulin‐like growth factor 
binding protein 3 
Inter‐alpha‐trypsin 
inhibitor heavy chain H1 
Inter‐alpha‐trypsin 
inhibitor heavy chain H2 
Inter‐alpha‐trypsin 
inhibitor heavy chain H3 
Inter‐alpha‐trypsin 
inhibitor heavy chain H4 
Interferon gamma 
Interleukin 1 
Interleukin 1 alpha 
Interleukin 1 beta 
















Interleukin 6 receptor 














Keratin, type I 
cytokskeletal 10 
Keratin, type I cytoskeletal 
13 
Keratin, type I cytoskeletal 
14 
Keratin, type I cytoskeletal 
9 
Keratin, type II cytoskeletal 
1 
Keratin, type II cytoskeletal 
2 epidermal 
Keratin, type II cytoskeletal 
2 oral 
Keratin, type II cytoskeletal 
5 
Keratin, type II cytoskeletal 
6A 
Kininogen‐1 
L‐lactate dehydrogenase A 
chain 













Liver carboxylesterase 1 
Long chain 
polyunsaturated fatty acids 




































MHC class I polypeptide‐
related sequence A 
Midkine 
MK‐1775 
Mucin‐like protein 1 




phenolic glycolipid I 
antibody 
Myeloid differentiation 









































Phosphoglycerate kinase 1 











Plasmodium vivax antibody 
Platelet basic protein 





factor B homodimer 
Platelet‐derived growth 
factor subunit B 
Pregnancy‐associated 
plasma protein A 
Procalcitonin 









complex subunit 2 
Proteasome inhibitor PI31 
subunit 
Proteasome subunit alpha 
type‐2 
Proteasome subunit alpha 
type‐3 
Proteasome subunit beta 
type‐1 
Proteasome subunit beta 
type‐4 














Proteins Induced by 






Putative protein FAM10A4 
Pyruvate kinase isozymes 
R/L 




Ras‐related protein Rab‐14 









Respiratory syncytial virus 
antibody 
Retinal dehydrogenase 1 
Retinol‐binding protein 
Ribonuclease inhibitor 
Rickettsia conorii antibody 
Rickettsia typhi antibody 
Rift Valley Fever Virus 
antibody 















Salmonella LPS Group B 
antibody 
Salmonella LPS Group D 
antibody 
Saponin C 
Saposin C  
Schistosoma antibody 






phosphatase 2A 65 kDa 





Serum amyloid A 
Serum amyloid A‐4 protein 
Serum amyloid P 












Solute carrier family 2, 
facilitated glucose 
transporter member 1 
Somatotropin 
Sorcin 
Spectrin alpha chain, 
erythrocyte 
Spectrin beta, erythrocytic 
Stathmin 














T‐complex protein 1 
subunit beta 
T‐complex protein subunit 
epsilon 
T‐complex protein subunit 
zeta 



























































Tropomyosin alpha‐1 chain 












Tumor necrosis factor 
alpha 
Tumor necrosis factor beta 
Tumor necrosis factor 
ligand superfamily member 
14 
Tumor necrosis factor 
ligand superfamily member 
8 
Tumor necrosis factor 
receptor 1 
Tumor necrosis factor 
receptor 2 
Tumor necrosis factor 
receptor superfamily 
member 4 


























UV excision repair protein 




growth factor A 
Vascular endothelial 
growth factor receptor 2 
Vascular endothelial 
growth factor‐D  
Vibrio cholerae antibody 
Vitamin D‐binding protein 
Vitronectin 
von Willebrand factor 
Zinc alpha 2‐glycoprotein 
Zinc finger protein 410 
Zinc finger protein 611 
Zymogen granule protein 
16 homolog B  
 
NUCLEIC ACID 
‐173 G/C SNP 
‐794 CATT(5‐8) 
1078delT gene mutation 
1717 1G‐>A gene mutation 
1726G>A gene mutation 
1898+1G‐>A gene 
mutation 
2183‐AA‐>G gene mutation 
22q11.2 gene deletion 
2789+5G‐>A gene 
mutation 





3905insT gene mutation 
621+1G‐>T gene mutation 
711+1G‐>T gene mutation 
A455E gene mutation 
A985G gene mutation 
ABCB1 C1236T 
polymorphism 
Alpha‐1 antitrypsin gene S 
mutation 
Alpha‐1 antitrypsin gene Z 
mutation 
Alpha‐globin gene 








BMP7 gene mutation 
Brugia malayi DNA 
BTD gene 

















































































Cluster E6 gene mutation 
CSF1PO locus 
CYP2D*15 gene mutation 
CYP2D6*11 gene mutation 
CYP2D6*12 gene mutation 
CYP2D6*14 gene mutation 
CYP2D6*19 gene mutation 
CYP2D6*20 gene mutation 
CYP2D6*3 gene mutation 
CYP2D6*4 gene mutation 
CYP2D6*6 gene mutation 























Del 8 bp E3 gene mutation 
Del 8bp E3 gene mutation 
delta‐F508 gene mutation 




FAT1 gene mutation 
FGA locus 
FGF12 gene mutation 
Fragile X mental 
retardation 1 gene 
G2677T/A polymorphism 
G542X gene mutation 
G551D gene mutation 
G6PD gene 




GJB2 gene mutation 




GTPCH gene mutation 
Hepatitis B virus 
Hepatitis B virus DNA 
Hepatitis C virus RNA 
Hepatitis E virus RNA 







HIV‐1 total nucleic acid 













HPRT1 gene mutation 
HTR2A gene locus 
Human cytomegalovirus 
DNA 
Human herpesvirus type 6 
DNA 





I172N gene mutation 
I2 splice (655A/C>G) gene 
mutation 
I2 splice gene mutation 
I236N/V237E/M239K 
(Cluster E6) gene mutation 




IL28 gene mutation 
Interferon gamma mRNA 







Loa loa DNA 
Mansonella ozzardi DNA 
Mansonella perstans DNA 
MBL2 gene 
Measles virus DNA 
N1303K gene mutation 
N314D gene mutation 
N51I gene mutation 
Onchocerca volvulus DNA 
p.I172N gene mutation 
p.L307fs gene mutation 
p.P30L gene mutation 
p.P453S gene mutation 
p.Q318X gene mutation 
p.R356W gene mutation 
p.R483P gene mutation 
p.V281L gene mutation 
P30L gene mutation 
P453 gene mutation 
PAX8 gene 
Penta D STR locus 
Penta E STR locus 
Pfcrt K76T polymorphism 
Pfdhfr gene 
Pfdhps gene 













Plasmodium knowlesi DNA 
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Plasmodium malariae DNA 
Plasmodium ovale DNA 




Q188R gene mutation 
Q318Stop gene mutation 
Q493X gene mutation 
R1162X gene mutation 
R117H gene mutation 
R334W gene mutation 
R347H gene mutation 
R347P gene mutation 
R356W gene mutation 
R483P gene mutation 
R553X gene mutation 
R560T gene mutation 
Rift Valley fever virus RNA 
rs1020636 gene locus 
rs1111366 gene locus 
rs11249784 gene locus 
rs11706962 gene locus 
rs1361861 gene locus 
rs1403294 gene locus 
rs1479530 gene locus 
rs1500098 gene locus 
rs1620329 gene locus 
rs1674139 gene locus 
rs17379 gene locus 
rs17407 gene locus 
rs1860665 gene locus 
rs1894697 gene locus 
rs1924609 gene locus 
rs222 gene locus 
rs228043 gene locus 
rs2282739 gene locus 
rs2289105 gene locus 
rs230 gene locus 
rs2303025 gene locus 
rs234 gene locus 
rs240 gene locus 
rs276922 gene locus 
rs326414 gene locus 
rs3784740 gene locus 
rs4240868 gene locus 
rs4306954 gene locus 
rs4358717 gene locus 
rs4763188 gene locus 
rs544021 gene locus 
Rubella virus RNA 
RYR2 gene locus 
S108N gene mutation 
S135L gene mutation 
S549N gene mutation 







T‐cell receptor excision 
circle 
TBX2 gene mutation 
TBX4 gene mutation 
TH01 locus 
Toxoplasma gondii DNA 
TPOX locus 
TSPAN1 gene mutation 
V281L gene mutation 
V520F gene mutation 
Visceral leishmaniasis DNA 
vWA locus 
W1282X gene mutation 
West nile virus RNA 
Wuchereria bancrofti DNA 
Y122X gene mutation 



































Table 2-4. Comprehensive list of analytic methods identified in the literature to have been 
applied to dried blood spots.  
 
MASS SPECTROMETRY 
Atmospheric pressure thermal desorption chemical 
ionization mass spectrometry 
Capillary electrophoresis mass spectrometry 
Capillary electrophoresis‐electrospray ionization‐mass 
spectrometry 
Desorption electrospray Ionization mass spectrometry 
Digital microfluidics mass spectrometry 
Electrospray ionization mass spectrometry 
Electrospray ionization tandem mass spectrometry 
Electrospray ionization triple‐quadrupole mass 
spectrometry 
Fast atom bombardment tandem mass spectrometry 
Flow injection analysis electrospray ionization tandem 
mass spectrometry 
Flow injection analysis tandem mass spectrometry 
Gas chromatography electron capture mass 
spectrometry 
Gas chromatography mass spectrometry 
Gas chromatography mass spectroscopy selective ion 
monitoring 
Gas chromatography tandem mass spectrometry 
Hydrophilic interaction liquid chromatography mass 
spectrometry 
Hydrophilic interaction liquid chromatography tandem 
mass spectrometry 
Inductively coupled plasma mass spectrometry 
Ion chromatography tandem mass spectrometry 
Ion trap mass spectrometry 
Isotope‐dilution mass spectrometry 
Isotope‐dilution tandem mass spectrometry 
Laser ablation inductively coupled plasma mass 
spectrometry 
Laser ablation inductively coupled plasma time‐of‐flight 
mass spectrometry 
Laser desorption mass spectrometry 
Laser diode thermal desorption atmospheric pressure 
chemical ionization tandem mass spectrometry 
Laser diode thermal desorption tandem MS 
Liquid chromatography atmospheric pressure chemical 
ionization mass spectrometry 
Liquid chromatography atmospheric pressure chemical 
ionization tandem mass spectrometry 
Liquid chromatography electrospray ionization mass 
spectrometry 
Liquid chromatography electrospray ionization tandem 
mass spectrometry 
Liquid chromatography multiple reaction monitoring 
mass spectrometry 
Liquid chromatography porous graphitized carbon time‐
of‐flight mass spectrometry 
Liquid chromatography time‐of‐flight mass 
spectrometry 
Liquid chromotagraphy mass spectrometry 
Liquid chromotagraphy tandem mass spectrometry 
Liquid microjunction surface sampling probe 
Liquid secondary ion tandem mass spectrometry 
Mass spectrometry 
Matrix‐assisted laser desorption/ionization high‐
resolution accurate mass mass spectrometry 
Matrix‐assisted laser desorption/ionization time‐of‐
flight mass spectrometry 
Matrix‐assisted laser desorption/ionization triple 
quadrupole mass spectrometry 
Microwave‐assisted silylation gas chromatography mass 
spectrometry 
Nanoelectrospray ionization mass spectrometry 
Nanoelectrospray ionization mass spectrometry digital 
microfluidics 
Negative‐ion chemical ionization mass spectrometry 
Negative‐ion chemical ionization tandem mass 
spectrometry 
Paper spray ionization multiple reaction monitoring 
mass spectrometry 
Paper spray mass spectrometry 
Reverse phase liquid chromatography electrospray 
ionization mass spectrometry 
Sector field inductively coupled plasma mass 
spectrometry 
Speciated isotope dilution mass spectrometry 
Tandem mass spectrometry 




Competitive enzyme‐linked immunosorbent assay 









Enzyme multiplied immunoassay technique 
Enzyme‐linked immunosorbent assay 
Fluorescence polarization immunoassay 
Fluorometric enzyme immunocapture assay 
Gelatin particle agglutination 
gG‐Capture enzyme immunoassay 
High‐throughput multiplex enzyme assay 
Immunoaffinity capillary electrophoresis 
Immunoassay 










Latex aggluniation test 
Micro‐card agglutination test for Trypanosomiasis 
Microscopic agglutination 
Microtiter plate‐based immunofluorescence assay 
Multiplexed fluorescent microsphere immunoassay 
Protein microarray 
Proximity extension immunoassay 
Radial immunodiffusion 
Radioimmunoassay 
Recycling immunoaffinity chromatography 
Silver‐enhanced gold‐labelled immunosorbent assay 
Treponema pallidum particle agglutination assay 
NUCLEIC ACID BASED 
Helicase dependent amplification assay 
High‐throughput sequencing 
Hybridization protection assay 
Loop mediated isothermal amplification 
Methylated DNA immunoprecipitation next generation 
sequencer 
Multiplex polymerase chain reaction 
Nested polymerase chain reaction 
Next‐generation sequencing 
Nucleic acid sequence‐based‐amplification 
Polymerase chain reaction 
Polymerase chain reaction oligonucleotide ligation 
assay 
Polymerase chain reaction‐restriction fragment length 
polymorphism 
Proximity ligation assay 
Proximity‐dependent DNA ligation 
Pyrosequencing 
Quantitative (or real time) polymerase chain reaction 
Real time reverse transcriptase polymerase chain 
reaction 
Real‐time quantitative nucleic acid sequence‐based 
amplification 
Reverse transcription polymerase chain reaction  
Selective acid lipase inhibitor enzyme assay 
TaqMan 5'‐nuclease assay 
Transcription mediated aplification hybridization 
protection assay 





Gas chromatography flame ionization detector 
Gas‐liquid chromatography 
Gel chromatography 
High performance capillary electrophoresis with 
fluoresence detection 
High‐performance anion‐exchange chromatography‐
pulsed amperometric detection 
High‐performance liquid chromatography 
High‐performance liquid chromatography ultraviolet 
radiation detection 






High‐performance liquid chromatography with 
fluorescence detection 
Hydrophilic interaction liquid chromatography 
Ion exchange chromatography 
Liquid chromatography 
Liquid chromatography colorimetry 
Liquid chromatography with fluorescence detection 
Liquid chromatography with ultraviolet radiation 
detection 
Reverse phase high‐performance liquid 
chromatography ultraviolet radiation 
Reverse phase ultra‐performance liquid 
chromatography 
SEPARATION (ELECTROPHORESIS) 




Lateral flow immuno‐chromatographic antigen‐
detection test 
Southern blot 





Ligand binding assay 
Microfluidics 
Microtiter transfer plates 
SPECTROSCOPY 






Graphite furnace atomic absorption assay 
Microtiter plate fluorometry 
Reflectometery 




Bacterial inhibition assay 
Cholesterol oxidase/p‐aminophenazone method 




Hemagglutination inhibition assay 
Indirect potentiometry 
Microbiological assay 








Figure 2-3. Percentage of analytic method categories assigned to unique analytic 




Table 2-5. SWOT analysis of common strengths, weaknesses, opportunities, and 
threats identified in the literature for dried blood spots. 
Strengths Weaknesses 
Minimally invasive 
Small sample volume 
Volumetric measurement  
Simple collection, transport, and storage 
Reduced biohazard risk 
Low cost 
Reduced material input and waste 
Compatible with most bioanalytical methods 
Versatile matrix 
Wide range of analytes validated 
Good precision and reproducibility 
Improved analyte stability 
Federal quality assurance program 
Federally established guidelines 
Published recommendations for validation methods 
Nontraditional sample matrix 
Small sample volume 
Sampling from cold or dehydrated persons 
Required drying 
Pathogenicity of agents 
Time, space, and labor intensive processing 




Differential analyte stability 
Differential analyte extraction efficiency 
Poorly defined regulatory landscape 
Additional validation steps 
Variability in validation methods applied 
Opportunities Threats 
Compliance with the 3Rs 
Centralization of labs 
Increased outpatient and offsite services 
Advancements in bioanalytical instruments 
Cost and availability of sophisticated 
instrumentation 
Microfluidics and nanotechnology 
Online/direct analyses 
Endogenous indicators of blood hematocrit 
Use of molar ratios 
Sampling in hard-to-reach and vulnerable 
populations 
Large, complex study design needs 
In-field forensics 
Other dried matrices 
Use of residual samples 
Pediatric involvement in studies 
Existing assays and workflows 




Table 2-6. Comparison of dried blood spots to traditional liquid plasma and serum. 
Characteristics Dried Blood Spots Traditional Plasma/Serum 
Matrix source Capillary blood (contains interstitial 
and intracellular fluids) 
Venous blood 
Matrix type Whole blood Plasma or serum 
Matrix state Dried Liquid or frozen 
Volume < 50 microliters (i.e., microsample) Several milliliters 
Collection Ambient delayed storage  
(i.e., open air drying followed by 
ambient storage) 
Cold immediate storage  
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Improved Methods for Field Collection and Storage of Dried 
Blood Spots 









Background: Dried blood spots (DBS) are a minimally invasive method for the collection 
of small quantities of whole blood, including cells and plasma, from finger or heel stick 
with application to specially designed filter paper cards for drying and storage. Existing 
guidelines for DBS collection require open-air drying for a minimum of 3 hours prior to 
storage. This requirement limits the use of DBS in field settings as logistical constraints 
and environmental conditions in the field may not be conducive to open-air drying. 
Samples left out for extended periods of time can be exposed to dust, insects, and other 
environmental contaminants, which may impact measurements from DBS samples. 
Additionally, highly humid environments can more than double drying times, which add 
substantial bias to sample measurements. Therefore, the ability to store DBS samples 
quickly after collection while achieving reductions in the variability of drying conditions 
could substantially improve analyte measurements from DBS samples.  
 
Objective: The objective of this study was to develop and validate new methods in DBS 
collection aimed at improving the reliability and stability of analyte measurements from 
DBS samples, especially those collected under challenging field conditions. We 
hypothesized that DBS samples stored quickly after collection in novel DBS kits would 





Methods: We measured drying times of blood spots collected in novel DBS collection kits. 
Kits were tested under ambient lab conditions of moderate humidity and ambient field 
simulation conditions of high humidity in the rainforest exhibit of the National Aquarium 
in Baltimore, Maryland. Drying times of blood spots were measured by use of resistance 
sensors that measure the resistance of currents in an electrical circuit that we specially 
designed for use with filter paper cards for this experiment. 
 
Results: Novel DBS collection kits were developed and tested under both moderate and 
high humidity conditions. Our kits demonstrated blood spot drying times of less than 90 
minutes. Moreover, DBS samples collected with these kits under moderate and high 
humidity ambient conditions had blood spot drying times approximately 30% and 50% 
faster respectively than open-air drying under similar conditions reported in the literature. 
Our kits remove the requirement of open-air drying, and may improve data quality by 
removal of potential bias introduced to DBS samples drying under variable environmental 
conditions. 
 
Conclusion: Our novel DBS collection and storage kits can enable improved field use of 
DBS by allowing for storage quickly after collection rather than open-air drying for 3 
hours. Moreover, our kits showed overall improvements in blood spot drying times that 
compare favorably with existing literature that indicate blood spots require a minimum of 
90 minutes to dry under conditions of low to moderate humidity, and greater than 150 
 
 90 
minutes in conditions of high humidity. Findings suggest our kits allow for storage of DBS 
samples immediately after collection, thereby preventing exposure to environmental 
contaminants, enabling movement of samples immediately following spotting to filter 
paper cards, and may provide overall improvements in data quality due to the removal of 




Dried blood spots (DBS) are a minimally invasive method for the collection of small 
volumes of blood (< 50 microliters) from finger or heel stick and transfer to filter paper 
cards for drying and storage [1-2]. In principle, anything that can be measured from liquid 
whole blood, plasma or serum, can be measured in dried blood spots [3]. All major 
categories of analytic methods have been applied for measuring analytes in DBS, including 
electrophoresis, immunoassay, chromatography, mass spectrometry, spectroscopy, and 
polymerase chain reaction (PCR) [4]. To date, DBS samples have been used for measuring 
over 1,900 different analytes, and have been applied to a variety of uses in basic research, 
public health, and clinical medicine [4]. 
 
The simplicity of collection methods and small volume of blood sample enable DBS to be 
collected without the need for a trained phlebotomist [5-6]. Additionally, the use of a dried 
matrix allows for ambient shipping and storage, and removes the requirement for cold 
chain, which is necessary for traditional liquid samples such as whole blood, plasma, and 
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serum [5-6]. These benefits make DBS a preferred method for the collection of biosamples 
in the field (i.e. outside of the traditional clinic or lab setting). However, some limitations 
in the methods for DBS collection continue to impede wider adoption in a range of settings. 
Variability inherent in rates of drying blood samples, and a minimum requirement of 
several hours open-air drying prior to sample storage or shipment are often cited as 
constraints on wider adoption of DBS [7-9]. As the quality and availability of highly 
sensitive analytical instrumentation, such as mass spectrometry, continue to improve, 
constraints around detection limits and variability in measuring analytes from DBS have 
become less of an impediment to adoption [10-11]. Yet the issue of open-air drying remains 
unresolved. 
 
The current collection protocol recommended by the United States Centers for Disease 
Control and Prevention (CDC) requires a minimum open-air drying time of 3 hours prior 
to sample storage [12]. This requirement is problematic in many settings of sample 
collection, including field collection studies. Open-air drying is logistically difficult during 
field collection as space for drying racks may not be available, conditions are often not 
conducive to drying (e.g. high humidity in tropical climates), and in the case of household 
surveys or other technically challenging environments such as occupational or austere 
settings, open-air drying for several hours may not be acceptable or feasible [6, 13-14]. 
Open-air drying in field settings also increase the risk of sample exposure to dust, chemical 
contaminants ubiquitous in the environment, airborne pathogens, and small insects to name 
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a few [15-16]. These risks are particularly problematic when target analytes include DNA 
or environmental contaminants, as sample measurements of either may actually reflect 
sample exposures during drying rather than host exposures prior to sample collection [16]. 
Variable ambient conditions of humidity also affect the drying times of DBS samples, 
which is problematics as drying times have a direct impact on measurements for a range of 
target analytes, particularly metabolites, RNA, and all classes of analytes susceptible to 
hydrolysis, or other processes utilizing water for analyte degradation [7, 17-19]. In 
conditions of low or moderate humidity (i.e. relative humidity of less than 60%) drying 
times of 90 minutes are reported, whereas in conditions of high humidity (i.e. relative 
humidity equal to or greater than 60%) drying times as high as 150 minutes or more have 
been reported [20-21]. The ability to dry and store DBS samples shortly after blood 
collection, without compromising drying times, while also reducing variability of drying 
conditions that affect analyte stability, could enable wider adoption of DBS sampling in a 
range of settings, especially field settings, and may provide better quality measurements.  
 
The objective of this study was to demonstrate proof-of-concept for a novel DBS collection 
kit aimed at enabling field collection and storage. We hypothesized that our novel 
collection kits will enable storage of DBS samples quickly after collection without 
compromising drying times. Specifically, we hypothesized that DBS samples stored in our 
kits immediately after collection would have average drying times of less than 90 minutes 
in conditions of low to moderate, or high humidity. Storage quickly after blood collection 
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in kits protected from environmental exposures, and which improve drying times, could 





Kit Selection and Justification 
The goal of kit selection and optimization was to design and optimize a kit that maintained 
the simplicity of DBS methods such that they could be used effectively in field settings. 
Inclusion criteria for kit design and fabrication were as follows: 
1. Kit materials must be commercially available. 
2. Kit contents must not require any additional manufacturing or engineering beyond 
the point of procurement/purchasing. 
3. Kit contents must be easily put together by end users in the field.  
 
Novel DBS collection kits were designed with a closed-system (i.e. airtight containers 
protected from the external environment) by inclusion of an opaque, airtight, cylindrical 
container with an optimized amount of molecular sieve desiccant, and use of a DBS filter 
paper card. The container selected included a 644 mL aluminum, opaque, cylindrical bottle 
(75 mm diameter and 152 mm height) with screw-on cap from Elemental Container (Figure 
3-1a; product # 0075152). The use of an opaque container was selected in order to meet 
current recommendations for drying DBS samples away from direct sunlight, which could 
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be an issue during field collection as personnel may need to move blood samples shortly 
after collection. The use of an airtight container was selected in order to allow control and 
modulation of the moisture conditions within the kit. The cylindrical shape and size of the 
container was selected to allow enough space for inclusion of desiccant, filter paper card, 
and wireless sensors with data loggers for measuring drying times of blood spots, and 
tracking relative humidity and temperature during experimentation. Molecular sieve 
MiniPax absorbent packets from Multisorb Technologies (Figure 3-1b; product # 02-
00041AG19) were used as the desiccant of choice, as opposed to the more common silica 
gel desiccant, due to their ability to absorb moisture faster and maintain moisture within 
the desiccant under dynamic or extreme temperature conditions, which were directly tested 
in our study as described herein under Stress Testing Methods. Whatman 903 filter paper 
cards from GE Healthcare Life Sciences (Figure 3-1c; product # 10531018) were selected 
for inclusion in the kits due to being the most commonly used type of filter paper card in 
DBS studies, as well as their history of rigorous quality assurance testing from CDC [22-
23]. The optimal amount of molecular sieve (i.e. 40 grams) was determined experimentally 
and was based on the volume of air within the selected kit container, type of filter paper 
card, and expected amount of moisture introduced into the closed-system by a freshly 
spotted filter paper card. More specifically, in preparation for our study, we conducted a 
series of experiments with increasing amounts of molecular sieve desiccant within our kits 
in order to determine the optimal amount of sieve for removing moisture from the closed-
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system. We have detailed these methods and reported our findings in Appendix A under 
Supplementary Materials.  
 
Drying Rate Methods  
Goal: The goal of the drying rate experiments was to determine the time required for blood 
on filter paper cards to dry within our novel DBS collection kits. We defined drying in our 
experiment as the time at which specially designed resistance sensors, as described below, 
achieved a stable measurement, which indicated all detectable moisture had evaporated 
from the blood spot.  
 
Outcome Measures: The outcome measures of interest included (1) time required for 
freshly spotted human whole blood to dry on filter paper cards within DBS kits and (2) 
time required for the relative humidity (RH) inside kits to reach near zero moisture levels, 
defined here as an RH level of less than 0.01%. As we were interested in the time required 
for spots to dry within a closed system, common approaches such as periodic weight 
measurements of filter paper cards could not be used. In consultation with the Biomedical 
Engineering Department at Johns Hopkins University, we developed a novel method for 
measuring drying time. Specifically, we utilized resistance, which is a measure of 
opposition to passage of electric current through a media, in this case, blood on filter paper 
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[24]. As spots dry on filter paper cards and conductivity of the current reduces, resistance 
measurements will eventually begin to drop and stabilize once the spot is dry3.  
 
Materials: Kit containers were procured directly from Elemental Container; 10 g molecular 
sieve desiccant packets and Whatman 903 cards were procured from Sigma-Aldrich; 
wireless bluetooth enabled RH/temperature HOBO data loggers (Figure 3-1d; product # 
MX1101) were procured from ONSET; and 200 microliter adjustable pipettes (product # 
3121000082) were procured from Eppendorf. For measuring drying rate of blood spots, a 
resistance measuring and storage system was designed and built from scratch by 
assembling components procured from the online digital electronics retailers Adafruit and 
Sparkfun. Specifically, we assessed drying through resistance across blood spots as 
measured by applying a constant DC voltage of 3.7V with the help of a lithium polymer 
battery (product #2011). The data obtained from this system was stored in a data logger 
(product #1895). The data collection, storage, and retrieval was managed using an Arduino 
pro mini microcontroller (product #2377). Additionally, a circuit scribe conductive ink pen 
(product # COM-13254) was procured from Sparkfun, and mini alligator clips (product # 
CZACA) were procured from Amazon. After procurement, all components were soldered 
together and the sensor designed as show in the circuit diagram (Figure 3-2). We then 
designed and wrote an Arduino program for logging resistance data from sensors during 
                                                     
3 We cross‐validated the use of resistance for measuring drying weights (data not shown) outside of the 
closed‐system kits by real time monitoring of resistance measurements at 1‐minute intervals followed by 
weight measurements of filter paper cards with a microscale before and after resistance levels stabilized.  
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experimentation. 30 mL of fresh donor human whole blood (i.e. collected less than 48 hours 
from time of experimental use) with sodium citrate anticoagulant was procured from 
Innovative Research (product # IPLA-WB1).  
 
Process: Drying rate experiments were conducted under ambient lab conditions, which 
included a temperature range of 22-24℃ and moderate humidity (30-50% RH), and under 
simulated field conditions of 24-25℃ and high humidity conditions (>50% RH) in the 
rainforest exhibit of the National Aquarium in Baltimore, Maryland. All experiments 
utilized the same study design, which included 6 replicate kits with optimized amounts of 
molecular sieve desiccant and filter paper cards freshly spotted with human whole blood. 
Specifically, we used circuit pens (product # COM-13254) to draw an electric circuit onto 
filter paper cards (Figure 3-1e) and attached mini alligator clips, which were connected to 
the microcontroller circuit. We would then start HOBO and resistance sensor data logging 
at 1-minute measurement intervals, spot a total of four 30 uL spots of human whole blood 
via micropipette onto Whatman 903 filter paper cards, and immediately placed the spotted 
cards, HOBO sensors, resistance sensors, and optimized amount of molecular sieve 
desiccant into the containers and sealed them (Figure 3-1f). Experiments were carried out 
for 24 hours, after which time containers were unsealed, HOBO and resistance sensors 
were stopped, and data was downloaded in Excel and CSV formats to a desktop computer. 




Analysis: We inspected resistance measurements and recorded drying time by measure of 
the Time to Stability (TTS), defined here as the minutes required for resistance 
measurements to decrease and stabilize. The mean and standard deviation for drying times 
of all 6 replicates in each experiment was calculated. The mean and standard deviation for 
time required to reach near zero moisture levels was also calculated. Two-sample t-tests 
were conducted to determine if the differences in drying times between the three 
experiments was significant.  
 
Extended Storage Methods 
Goal: The goal of the extended storage experiment was to determine if near zero moisture 
levels (<0.001% RH) inside DBS kits was maintained for at least 14 days of storage.  
 
Outcome Measure: The outcome measure for the extended storage experiment was RH.  
 
Materials: Containers, desiccant, DBS cards, RH/temperature data loggers, pipettes, and 
human whole blood were procured as previously specified.  
 
Process: 6 replicate kits with optimized amounts of molecular sieve desiccant and filter 
paper cards were freshly spotted with human whole blood and included in the extended 
storage experiment. Specifically, we began by starting HOBO sensor data logging at 1-
minute measurement intervals, then spotted four 30 uL spots of human whole blood via 
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micropipette onto Whatman 903 filter paper cards, and immediately placed the spotted 
cards, HOBO sensors, and optimized amount of molecular sieve desiccant into the 
containers and sealed them. The experiment was carried out for 14 days, after which time 
containers were unsealed, HOBO sensors were stopped, and data was downloaded in Excel 
and CSV formats to a desktop computer. Data was then imported into Stata version 13.1 
for analysis.  
 
Analysis: RH values were inspected to determine time required for near zero moisture 
levels to be achieved, and determined if RH levels rose above near zero moisture levels at 
any time thereafter. 
 
Stress Test Methods 
Goal: The goal of the stress test experiment was to determine if near zero moisture levels 
were maintained by molecular sieve desiccants under temperature extremes (i.e. does 
moisture escape from the sieve under extreme heat or cold).  
 
Outcome Measure: The outcome measure for the extended storage experiment was RH.  
 
Materials: Containers, desiccant, DBS cards, RH/temperature data loggers, pipettes, and 
human whole blood were procured as previously specified. An environmental chamber was 
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procured on loan from the Johns Hopkins University Applied Physics Laboratory (Figure 
3-1H), and a minus twenty freezer was already present in the lab for experimentation.  
 
Process: 6 replicate kits with optimized amounts of molecular sieve desiccant and filter 
paper cards were freshly spotted with human whole blood and included in the stress testing 
experiment. Specifically, we began by starting HOBO sensor data logging at 1-minute 
measurement intervals, then spotted 4-30 uL spots of human whole blood via micropipette 
onto Whatman 903 filter paper cards, and immediately placed the spotted cards, HOBO 
sensors, and optimized amount of molecular sieve desiccant into the containers and sealed 
them. We allowed moisture levels inside the kits to reach near zero levels before beginning 
stress testing. After near zero moisture levels were achieved, kits were placed inside of an 
environmental chamber and heated to > 38℃. Kits were then removed from the 
environmental chamber and allowed to return to ambient conditions. After returning to 
ambient conditions, kits were placed inside a freezer and cooled to below 0℃, after which 
time containers were removed from the freezer and allowed to return to ambient 
temperatures. After returning to ambient temperatures, kits were unsealed, HOBO sensors 
stopped, and data downloaded in Excel and CSV formats to a desktop computer. Data was 
then imported into Stata version 13.1 for analysis.  
 
Analysis: RH values were inspected to determine if RH levels rose above near zero 







Lab-based drying rate experiments were conducted under ambient lab conditions. 
Experimental data is reported in Table 3-1. Temperatures in the lab during drying for lab-
based experiment 1 ranged between 22 and 24℃ with an ambient RH between 33 and 35%. 
Mean resistance-based blood spot drying time for lab-based experiment 1 was calculated 
at 47.6 minutes (n = 5, SD = 4.51)4. The mean time required to achieve near zero moisture 
conditions inside kit containers for lab-based experiment 1 was calculated at 603.8 minutes 
(n = 6, SD = 100.9), or approximately 10 hours. Ambient conditions for lab-based 
experiment 2 were similar to experiment 1, as were the recorded blood spot drying times. 
Specifically, temperatures in the lab during drying for lab-based experiment 2 ranged 
between 22 and 23℃ with an ambient RH between 33 and 35%. Mean resistance-based 
blood spot drying time for lab-based experiment 2 was calculated at 53.3 minutes (n = 6, 
SD = 6.95). The mean time required to achieve near zero moisture conditions inside kit 
containers for lab-based experiment 2 was calculated at 423.2 minutes (n = 6, SD = 61.1), 
or approximately 7 hours. A two sample t test was calculated for comparing experiments 1 
and 2. No significant difference in blood spot drying times was detected between 
                                                     
4 Lab‐based experiment 1 and field simulation have an n of 5 for mean drying time due to resistance 
sensor failures during experimentation. RH sensors operating during these same experiments functioned 




experiments 1 and 2 (df = 9, t = 1.58, p = 0.1482). Visual inspection of RH curves for 
experiments 1 and 2 had similar findings (Figure 3-3 and Figure 3-4). Specifically, an 
initial increase above starting RH levels of 5-10% was detected for all 6 replicates, 
followed by rapid RH depletion until RH fell below 20%, after which time RH depletion 
slows until near zero moisture is achieved.  
 
In order to simulate high humidity field conditions, a field simulation experiment was 
conducted in the rain forest exhibit of the National Aquarium in Baltimore, Maryland. Data 
for the field simulation is reported in Table 3-1. Temperatures in the rain forest exhibit 
during drying ranged between 24 and 25℃ with an ambient RH between 49 and 61%. 
Mean resistance-based drying time for the field simulation was calculated at 72.4 minutes 
(n = 5, SD = 13.39). The mean time required to achieve near zero moisture conditions 
inside kit containers for the field simulation was calculated at 558.5 minutes (n = 6, SD = 
139.8), or approximately 9 hours. Two sample t-tests were calculated for comparing blood 
spot drying times in the field simulation with the lab-based experiments. A significant 
difference in drying times was detected for the field simulation versus lab-based 
experiment 1 (df = 8, t = 3.93, p = 0.0044). A significant difference in drying times was 
also detected for the field simulation versus lab-based experiment 2 (df = 9, t = 3.05, p = 
0.0138). Visual inspection of the RH curves for the field simulation found a different shape 
than what was found for the lab-based experiments (Figure 3-5). Specifically, there is an 
immediate drop of 5-10% in detected RH levels inside kit containers for all 6 replicates 
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followed by a leveling off of RH, and then a rapid decline until RH falls below 20%, after 




Extended Storage and Stress Test 
Extended storage and stress test experimental findings were unremarkable. After achieving 
near zero moisture conditions within containers, all 6 replicates maintained near zero 
moisture throughout the 14-day storage period (Figure 3-6). Under stress testing, near zero 
moisture conditions were maintained for all 6 replicates under conditions of extreme heat 
and cold. Specifically, neither heating kits to > 38℃ nor cooling kits to below freezing (i.e. 
< 0℃) resulted in any detectable moisture being released by the molecular sieve desiccant 




Consistent with the study’s hypothesis, findings suggest that our novel DBS collection and 
storage kits can remove the requirement of open-air drying, while reliably drying DBS 
samples in less than 90 minutes in low to moderate or high humidity conditions. Though 
low humidity conditions were not directly tested in this experiment, both moderate and 
high humidity conditions demonstrated mean drying times of less than 90 minutes, and 
would suggest that low humidity conditions would perform similarly well, if not better. 
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Both experiments conducted under ambient conditions of moderate humidity demonstrated 
mean drying times of less than 60 minutes, which compares favorably with previous studies 
citing 90-minute drying times for similar ambient conditions [20-21]. These findings 
represent approximately a 30% improvement in blood spot drying compared with open-air 
drying. Kit performance under ambient conditions of high humidity compared with open-
air drying under similar conditions was even more pronounced. Mean drying times for DBS 
samples in kits during field simulation in the high humidity environment of the rainforest 
exhibit at the National Aquarium in Baltimore were less than 75 minutes, which represents 
approximately a 50% improvement in blood spot drying compared with previous studies 
citing as high as 150 minutes or more under high humidity [20-21].  
 
In contrast to ambient conditions of moderate humidity, which demonstrate an immediate 
increase in the internal RH conditions of kits, ambient conditions of high humidity 
demonstrated an immediate decrease in the internal RH conditions of kits. In the case of 
an immediate increase in internal RH conditions inside kits compared with the external 
environment, it could be inferred that drying conditions for DBS samples inside our kits 
used in moderate or low humidity conditions are initially worse than open-air drying in 
similar conditions. However, drying times suggest this is not the case. The initial increase 
in RH detected within kits may simply be a result of moisture being transferred quickly 
through the air as it is removed from blood spots and absorbed by the molecular sieve. In 
the case of an immediate decrease in internal RH conditions inside kits compared with the 
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external environment, as was detected in the RH curves for the field simulation, it is 
reasonable to assume that drying conditions inside the container are better than open-air 
drying under similar conditions of high humidity within a minute of sealing the container. 
These findings suggest our kits would be a preferred method of DBS collection over the 
current protocol in conditions low to moderate or high humidity. 
 
Stress tests indicate that molecular sieve desiccants do, in fact, retain moisture even under 
extreme temperature conditions, and may therefore be the preferred desiccant of choice for 
maintaining a near moisture free environment around DBS samples when in transport and 
storage, particularly in field settings where temperature conditions cannot be controlled. 
Extended storage tests suggest that kits can be effectively used as storage containers for a 
minimum of 14 days. Taken together with improvements in drying times, study findings 
suggest that our novel DBS collection and storage kits may be a preferred method for DBS 
sampling in field settings by removing the requirement of open-air drying, allowing for 
immediate storage, and potentially improving data quality by stabilizing analytes and 
preventing contamination. Potential improvements in analyte stability due to faster or more 
consistent drying times, particularly for metabolites, RNA, and other classes of analytes, 
which are susceptible to degradation by hydrolysis, should be demonstrated 
experimentally. We did not directly measure analyte stability for DBS samples collected 





Study limitations around ambient conditions for experimentation, storage times and 
stressing should be noted. As molecular sieve desiccant action is temperature dependent, 
additional experimentation with use of our novel kits should include a wider range of 
ambient temperatures [25]. Longer storage times would also provide a benefit to potential 
end-users. Stress testing of kits under extremes greater than 38℃ may also be warranted 
as field conditions could easily exceed the upper limit of the heat conditions of our stress 
test. Use of fresh blood, rather than sodium citrate treated blood should also be tested as 
anticoagulant use may affect drying rate of blood spots. 
 
Conclusion 
Our novel DBS collection and storage kits developed can enable improved field use of 
DBS by removing the requirement for open-air drying and allowing quick storage after 
collection with overall improvements in blood spot drying times. Immediate storage and 
faster drying times could reduce the logistical constraints around DBS collection in the 
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TABLES AND FIGURES 
 




External Ambient Conditions 
During Drying 
Resistance-Based 
Drying Time  
(Mean + SD) 
Time Required to Achieve 
Near Zero Moisture in 
Kits (Mean + SD) 
Lab-Based 1 RH = 33-35%  T=22-24℃ 47.6 + 4.5 min (n=5) 604 + 101 min  
or ~10 hours (n=6) 
Lab-Based 2 RH = 33-35%  T = 22-23℃ 53.3 + 7.0 min (n=6) 423 + 61 min  
or ~7 hours (n=6) 
Field Simulation 
(Rainforest) 
RH = 49-65%  T = 24-25℃ 72.4 +13.4 min (n=5) 559 + 140 min  
















Figure 3-3. Internal moisture conditions for DBS kits during lab-based drying 
rate experiment 1.  
 
Figure 3-4. Internal moisture conditions for DBS kits during lab-based drying 





Figure 3-5. Internal moisture conditions for DBS kits during field simulation 
drying rate experiment in the Rainforest Exhibit of the National Aquarium 
(Baltimore, Maryland, USA). 
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Improved Methods for Collection and Storage of Dried Blood 
Spots for RNA Detection and Quantification 









Background: The ability to collect and analyze biosamples in settings outside of the 
traditional clinic or lab environment is essential to basic research, public health, and clinical 
medicine. Unfortunately, collection of traditional samples such as liquid whole blood, 
plasma, and serum require phlebotomy and cold chain, neither of which may be available 
outside of the lab or clinic. Dried blood spots provide a minimally invasive alternative 
method for the collection of biosamples without the need for phlebotomy or cold chain. 
However, the current methods recommended by CDC for DBS collection require open-air 
drying of samples for a minimum of 3 hours, which may not be feasible in the field, and 
can lead to sample contamination. We have recently reported on novel methods in DBS 
collection that allow storage of DBS samples immediately after sampling, removing the 
requirement of open-air drying. This paper reports on the application of these methods to 
the measurement of gene transcripts in blood samples. 
 
Objective: The objective of our study was to investigate the performance of our novel DBS 
methods with the current methods recommended by CDC, as well as the current gold 
standards for venous blood collection, on the detection and quantification of messenger 
RNA (mRNA) in DBS samples. 
 
Methods: We used a validation of assay protocol for investigating the performance of our 
novel DBS collection methods on the detection and quantification of mRNA compared 
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with current DBS methods. We used quantitative RT-PCR (qRT-PCR) to assess abundance 
of 3 target gene transcripts (GBP5, DUSP3, KLF2) and 1 housekeeping gene transcript 
(GAPDH). Our study included samples from 16 individual donors. Samples included 
paired aliquots from each individual donor biosample prepared under novel and current 
methods, as well as a gold standard sampling method for mRNA analysis (PAXgene Blood 
RNA Tubes). Our analysis included percentage detection of mRNA above threshold levels 
for each sampling modality as well as analysis of transcript abundance measures by 
descriptive statistics (mean delta Ct values and coefficient of variation), correlation 
statistics and linear regression, and Bland-Altman analysis. 
 
Results: Our data suggests our novel methods provide as good or an improvement in 
performance for mRNA detection and quantification compared with current methods. 
Specifically, we found similar performance in mRNA detection for our novel methods 
compared with current methods, and improved performance in mRNA quantification over 
current methods. We found no significant differences in mean delta Ct values for our novel 
methods compared with gold standard measurements for 2 of 3 transcripts, whereas mean 
delta Ct values for current methods were significantly different from gold standard for all 
3 transcripts. We also found less variation in our novel methods compared with current 
methods for all 3 transcripts, suggesting our novel methods help reduce some of the 




Conclusion: Our novel methods in DBS collection and storage demonstrated an overall 
improvement in the detection and quantification of mRNA from DBS. We recommend our 




Methods for the collection and use of biological specimens (biosamples) for biological 
markers (biomarkers) measurement are essential tools in public health and medicine. 
Biosamples are used routinely in basic research, as well as in public health practice for 
surveillance and population-based studies among other applications [1-6]. Biosamples are 
also critical tools in clinical medicine. For example, biomarkers are commonly used for 
characterizing health status, diagnosing disease, and therapeutic drug treatment monitoring 
[2, 7]. Traditional biosamples, such as venous whole blood, plasma, and serum, however, 
may pose signficant challenges in collection and storage outside of the clinic, hospital, or 
laboratory settings [8]. Venous blood sample collection requires a trained phlebotomist as 
well as refrigeration or freezing of blood or blood constituents from time of collection until 
time of analysis, i.e., sustaining a reliable cold chain. In many environments, especially in 
remote or austere settings such as the Sahel where humanitarian efforts are common, 
phlebotomy and/or cold chain may not be available nor financially or logistically feasible 




An alternative method to the collection of venous whole blood, plasma, and serum in 
nontraditional, remote, or austere settings is dried blood spot (DBS) sampling. DBS is a 
minimally invasive method for the collection of small quantities of whole blood from finger 
or heel stick with transfer to specially designed filter paper cards for storage and transport 
[10]. Historically, DBS has been used in newborn screening programs, and is the most 
commonly used type of dried microsample in research, public health, and medicine [11-
12]. Among the advantages of DBS sampling methods, the ability to obtain a blood sample 
without a trained phlebotomist or cold chain has positioned DBS as a potential biosample 
matrix for use in non-traditional environments, and especially in remote and austere 
settings [8-9]. In recent years, as advancements in highly sensitive lab instrumentation and 
analytic software have emerged, interest in the use of DBS has increased, however, 
challenges in field collection remain an impediment to wider adoption [13-15]. 
Specifically, current recommendations in DBS methods require open-air drying for a 
minimum of 3 hours prior to storage and transport [16]. This requirement can be especially 
problematic in the field where space for drying may not be available, and prolonged open-
air drying could allow for sample contamination from dust, insects, and other 
environmental exposures [17-20]. Furthermore, variable drying conditions can 
significantly alter biomarker measurements. This is particularly problematic for 
biomarkers that are susceptible to hydrolysis or other processes that utilize water for 
degradation as greater variability in drying times result in greater variability in biomarker 
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measurements [21-24]. Evidence-based improvements in field collection of DBS samples 
would greatly facilitate wider adoption of the methodology. 
 
We recently developed novel methods for the field collection of DBS samples that control 
contamination and air drying [25]. These methods utilize small, opaque, air-tight kits with 
optimized amounts of molecular sieve desiccant for quickly drying DBS samples within a 
protected and closed environment. We reported faster drying times compared with open-
air drying in similar environments, and an ability to reduce variability in drying conditions 
- i.e., the ability to consistently dry DBS samples in less than 90 minutes in low, moderate, 
or high humidity conditions. Additionally, the ability to store DBS samples quickly after 
collection removes the requirement of open-air drying, which is likely to reduce the chance 
for sample contamination. 
 
In theory, faster drying rates in combination with less variation in drying conditions 
between sample collections should improve the precision of biomarker measurements from 
DBS samples, especially for biomarkers that are susceptible to degradation by hydrolysis 
or other processes utilizing water. Less variation in drying conditions alone is an incredibly 
important improvement as it can improve overall data quality. However, this hypothesis 
had not been tested for our novel DBS methods. Therefore, the objective of our study was 
to examine the performance of novel methods in DBS collection compared with current 
methods with respect to a particular analyte that is both broadly relevant to biomedical 
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research and clinical health monitoring, and subject to hydrolytic degradation in storage – 
messenger RNA (mRNA). We defined current methods as those presently recommended 
by the United States Centers for Disease Control and Prevention (CDC), which requires 
open-air drying for a minimum of 3 hours followed by storage in sealable, airtight, plastic 
bags with silica gel desiccant [16].  
 
Our selection of mRNA as the biomarker for this study was based on two factors. First, 
mRNA is a particularly problematic biomarker in traditional biosamples due to the effect 
of RNAse, which is ubiquitous in the biosamples themselves, as well as in the environment, 
and quickly degrade mRNA [23, 26]. As RNAse requires water for its degradation 
processes, faster or less variable drying rates could result in improved performance for 
DBS compared with traditional samples [26-28]. Second, current gold standard methods in 
mRNA analysis often require use of vacutainers and RNA stabilizing agents (e.g. PAXgene 
RNA Blood Tubes, RNAlater, etc.) following by freezing the biosample, which increases 
the overall cost and technical requirements for field collection and storage of biosamples, 
which may not be feasible in some settings [29]. The ability to use novel DBS collection 
methods in the field for detection and quantification of mRNA in biosamples could remove 
many of the existing hurdles to DBS adoption. We hypothesize that our novel DBS 
collection methods will demonstrate an overall improvement in performance for the 






Study Context and Design 
Study subjects were recruited and samples collected under informed consent at Johns 
Hopkins Medical Institutions in Baltimore, Maryland. Research protocols were approved 
by the Institutional Review Board (IRB) at the Johns Hopkins Bloomberg School of Public 
Health (IRB No: 00007621). A total of 18 subjects were enrolled prior to sample collection, 
and all biosamples were collected on a single day (24 March 2017). Samples from two 
subjects were removed from the study due to protocol deviations during biosampling. 
Sample size and the use of triplicate assay determinations (see Nucleic Acid Amplification 
and Determination) were based on best practices in the scientific literature and FDA 
guidance for bioanalytical method development [31-32]. The only inclusion criteria for 
subjects was that they be between the ages of 18 and 49 years. Our study design included 
a validation of assay protocol for comparing mRNA measurements between DBS 
methodologies (aka, sampling modalities) and liquid venous blood samples collected under 
gold standard laboratory methods using PAXgene Blood RNA Tubes (see Sample 
Collection and Preparation). We selected 3 gene transcripts associated with immune 
function as our target mRNA biomarkers (GBP5, DUSP3, KLF2), and 1 well-established 
housekeeping gene transcript for normalization of mRNA measurements (GAPDH) [33-
36]. We selected our target transcripts based on commercial availability of probes for qRT-
PCR and the requirement that they be constitutively expressed - i.e., we selected transcripts 
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that should be present at detectable levels in all study subjects irrespective of their 
individual health status or other factors. 
 
Sample Collection and Preparation 
A total volume of 30 mL venous blood was collected from each study subject by a trained 
phlebotomist with a standard venipuncture collection protocol at JHMI. The first 10 mL of 
blood were collected directly into a PAXgene RNA blood tube from BD Biosciences 
(Product No. 762165) containing anticoagulant and an RNA stabilizing agent. The 
remaining 20 mL were collected into a syringe containing citrate dextrose anticoagulant 
solution. PAXgene RNA blood tube samples, hereafter referred to as gold standard, served 
as our gold standard comparison for mRNA measurements. Gold standard samples for all 
study subjects were paired with matched DBS samples prepared under two different 
protocols. Both the PAXgene tubes and syringes were transported from the phlebotomy 
room to the lab (on the same floor as the phlebotomy room) for sample preparation and 
storage immediately following collection. PAXgene tubes were placed into a -20℃ freezer 
while the blood in the syringe, which contained citrate dextrose anticoagulant solution, was 
divided into four 5 mL conicals for DBS sample preparation. Four 30 uL drops of blood 
were spotted by micropipette onto Whatman 903 filter paper cards under ambient lab 




DBS samples were prepared and stored under two different DBS protocols. DBS protocol 
1, hereafter referred to as novel methods, included use of the novel methodologies we 
developed for enabling field collection of DBS samples. These methods include use of 
Whatman 903 filter paper cards from GE Healthcare Life Sciences (Product No. 10531018) 
with immediate storage after blood spotting into 644 mL aluminum, opaque, cylindrical 
containers with screw-on caps from Elemental Container (Product No. 0075152). Each kit 
contains an experimentally optimized 40 g of molecular sieve desiccant, as described in 
Chapter 3, from Multisorb Technologies (Product No. 02-00041AG19) for the purpose of 
quickly drying freshly spotted DBS samples within a closed system. 
 
DBS protocol 2, hereafter referred to as current methods, is the current protocol for DBS 
collection and storage as recommended by CDC [16]. The current methods include use of 
Whatman 903 filter paper cards, which are open-air dried on a rack for a minimum of 3 
hours prior to storage. Once dry, DBS cards are placed inside glassine envelopes and plastic 
bags along with humidity indicator cards, and silica gel desiccants for maintaining a low-
moisture environment during storage and transport. Our study used Whatman glassine 
envelopes (Product No. 28417400), Whatman plastic bags (Product No. 28417398), 
Humonitor humidity indicator cards (Product No. 2291DG03), and silica gel desiccant 
packs (Product No. 02-00040AG45). We procured all DBS materials for current methods 
from Sigma-Aldrich. After 24 hours following spotting, we prepared samples for shipment 
to the UCLA Social Genomics Core in Los Angeles, California for mRNA extraction and 
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analysis. PAXgene tubes were shipped on dry ice, while DBS samples collected under both 
novel and current methods were shipped overnight under ambient conditions (not 
recorded). After receipt at UCLA, PAXgene tubes were stored in a -20℃ freezer and DBS 
samples stored under ambient lab conditions (not recorded) for two weeks until mRNA 
extraction and assay. 
 
Nucleic Acid Extraction 
Total mRNA was extracted from PAXgene Blood RNA Tube samples using an automated 
nucleic acid processing system (Qiagen QIAcube) following a standard protocol derived 
from the PAXgene Blood RNA Kit Handbook from Qiagen (UCLA Social Genomics Core 
Laboratory SOP-45, Appendix A, Supplementary Materials) [50]. Total mRNA was 
extracted from DBS samples by suspending sheared DBS filter papers for 30 min in Qiagen 
RLT buffer (at 37°C with agitation) followed by extraction using an automated nucleic 
acid processing system (Qiagen QIAcube) following a standard protocol derived from the 
RNeasy® Micro Handbook from Qiagen and modified per manufacturer’s instructions for 
DBS processing (UCLA Social Genomics Core Laboratory SOP-44, Appendix B, 
Supplementary Materials) [51]. 
 
Nucleic Acid Amplification and Determination  
mRNA samples were assayed using standard qRT-PCR protocols implemented on a Bio-
Rad iQ5 real-time PCR system using reverse transcriptase and polymerase chain reaction 
 
 128 
enzymes and buffers appropriate for fluorescent probe-based detection (Qiagen 
QuantiTect® Probe PCR Kit) and standard commercially available primer/probe systems 
(Applied Biosystems TaqMan® Gene Expression Assays Hs00369472_m1, 
Hs01115776_m1, Hs00360439_g1, and Hs02786624_g1).  Reverse transcription and PCR 
thermal cycling protocols followed the assay manufacturer’s specified time/temperature 
profiles.  Procedures for mRNA amplification and quantitation followed a UCLA protocol 
adapted from the QuantiTect® Probe PCR Handbook from Qiagen (UCLA SOP-24, 
Appendix C, Supplementary Materials) [52]. All measurements were conducted in 
triplicate with median Ct values reported as final mRNA measurements for each of the gene 
transcripts. Ct values were then normalized to delta Ct values for statistical analysis. Delta 
Ct values were calculated for each of the 3 target gene transcripts by subtracting the 
corresponding Ct values of the housekeeping transcript (GAPDH), for the same sample and 
analytical run, from the target transcript. Due to our study design, Delta Delta Ct values 
were not considered for analysis. Delta Delta Ct calculations require an assumption of equal 
amplification efficiency, which could not be assumed due to our use of different collection 
modalities, which was required for testing our study hypothesis. 
 
Statistical Analysis  
We evaluated performance of both DBS methods against each other as well as against the 
gold standard. Detection performance was evaluated by percentage of samples detected 
above threshold levels, defined here as the percentage of samples within a sampling 
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modality that yielded detectable mRNA measurements above an auto-calculated threshold 
level (i.e., we used the Bio-Rad iQ5 PCR instrument’s default algorithm for identifying a 
valid detection threshold above background). These measurements enabled us to examine 
the extent to which our novel methods impacted the ability to detect mRNA from DBS 
samples. Quantitative performance was evaluated by descriptive statistics for each 
sampling modality (mean Delta Ct values and corresponding coefficient of variation), 
correlation and linear regression, Bland-Altman analysis, and Wilcoxon matched-pairs 
signed rank tests [37-39]. We used mean delta Ct and corresponding CV values in order to 
examine how our methods impact variability of mRNA measurements from DBS. We used 
correlation and linear regression to examine the degree to which our methods effect 
comparability of DBS measurements with gold standard. We used Bland-Altman analysis 
to examine the respective bias of our novel methods compared with gold standard in 
contrast to the current methods compared with gold standard. Finally, we used Wilcoxon 
matched-pairs signed rank tests to determine if mRNA measurements derived from our 
methods were significantly different current methods as well as from the gold standard. 
Significance levels for comparative analyses were set at 𝛼𝛼= 0.05. All analyses were 




Results are presented for mRNA measurements for 3 target gene transcripts (GBP5, 
DUSP3, KLF2), and 1 housekeeping transcript (GAPDH). mRNA measurements were 
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taken from blood samples from 16 subjects for two sets of matched DBS samples collected 
under our novel and current methods paired with PAXgene Blood RNA Tubes as gold 
standard. No personal identifying information of any kind was collected nor reported on 
study subjects. 
 
Percentage Detection Above Threshold 
To assess sampling modality performance on mRNA detection, the percent of samples 
achieving detectable mRNA above threshold levels were reported for all 16 samples 
collected under each of the 3 sampling modalities (Table 4-1). 100% of samples collected 
under gold standard methods yielded detectable mRNA levels for all 3 target gene 
transcripts as well as for the housekeeping transcript. As expected, gold standard methods 
outperformed both DBS sampling modalities. Findings suggest our novel methods had 
comparable performance in detection with current methods. Specifically, 100% of samples 
collected under novel methods versus 93.8% for current methods yielded detectable levels 
of GBP5. 81.3% yielded detectable levels of DUSP3 for both novel and current methods. 
81.3% for novel methods versus 93.8% for current methods yielded detectable levels of 
KLF2. Lastly, 93.8% of samples collected by both novel and current methods yielded 






Mean Delta Ct Values and Coefficient of Variation 
Mean delta Ct values and corresponding coefficients of variation (CV) were reported for 
comparing quantitative performance. Mean delta Ct values for novel methods were closer 
to gold standard measurements for 2 of 3 transcripts, and CVs for all 3 transcripts were less 
dispersed than were values from samples collected under current methods (Table 4-2). 
Specifically, GBP5 (n=14) mean delta Ct values were reported as 1.64 (CV=62.9%), 1.14 
(CV=137.2%), and 0.62 (CV=241.2%) for gold standard, novel methods, and current 
methods respectively. Mean delta Ct values for DUSP3 (n=8) were reported as 3.12 
(15.6%), 2.82 (45.2%), and 2.11 (66.0%) for gold standard, novel, and current methods 
respectively. Mean delta Ct values for KLF2 (n=12) were reported as 1.20 (CV=38.3%), 
2.14 (41.9%), and 1.41 (48.0%) for gold standard, novel, and current methods respectively. 
 
Wilcoxon Matched-Pairs Signed Rank Tests 
Wilcoxon matched-pairs signed rank tests were also used to compare matched delta Ct 
values for each of the 3 target gene transcripts for novel vs. gold standard, current vs. gold 
standard, and novel vs. current methods (Table 4-3). Delta Ct values for novel methods 
were not significantly different from gold standard for GBP5 (p=0.1205, n=15) or DUSP3 
(p=0.2810, n=13), whereas delta Ct values for current methods were significantly different 
for both GBP5 (p=0.0045, n=15), and DUSP3 (p=0.0339, n=13). Delta Ct values for novel 
and current methods were both significantly different than gold standard for KLF2 
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(p=0.0005, n=13; p=0.0026, n=15); however, they were not significantly different than 
each other (p=0.3013, n=12). 
 
 
Correlation Statistics and Linear Regression 
Correlation statistics are reported for novel and current methods compared with gold 
standard (Table 4) as well as compared with each other (Table 5). Linear regression plots 
are reported for novel and current methods compared with gold standard (Figure 1). 
Findings suggest novel methods had a neutral effect on quantification of mRNA compared 
with current methods as it pertains to correlation with gold standard. Specifically, both 
novel and current methods yielded significant positive correlations with gold standard for 
GBP5 (r=0.66, p=0.0070; r=0.60, p=0.0178), whereas neither method yielded significant 
correlation with gold standard for DUSP3 or KLF2. Novel and current methods were also 
significant positively correlated with each other for GBP5 (r=0.7442, p=0.0023), but not 
for DUSP3 or KLF2 (r=0.499, p=0.1182; r=-0.5076, p=0.920).  
 
Inspection of linear regression plots (Figure 1) and CV values (Table 2) suggests that the 
relatively poor correlation of DBS-derived results with gold standard results for DUSP3 
and KLF2 may stem in part from the relatively restricted range of underlying biological 
variation for these two transcripts relative to GBP5. Regression analysis shows clustering 
of values within a limited range of biological variation for both DUSP3 and KLF2 (both 
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~4-fold range of variation) whereas GBP5 showed substantially greater variation across 
participants (~16-fold range).  Note that these differences do not represent any decrement 
in assay precision for DUSP3 and KLF2 as replicate determinations actually showed lower 
CV values for these two analytes than did GBP5. 
 
Bland-Altman Analysis 
Findings from Bland-Altman analysis suggest novel methods had an overall neutral to 
positive effect on mRNA quantification as estimated biases for novel methods were smaller 
than for current methods in absolute terms (and comparable in confidence interval length) 
for 2 of 3 transcripts (GBP5 and DUSP3) (Table 6). Specifically, novel methods yielded 
biases of -0.4827 (-2.717 to 1.752) for GBP5, -0.3923 (-2.565 to 1.78) for DUSP3, and 
1.982 (-1.142 to 5.107) for KLF2. These values compare favorably with current methods’ 
bias statistics of -0.9927 (-3.267 to 1.282), -0.7115 (-3.026 to 1.603), and 1.121 (-1.151 to 
3.392), respectively. Bland-Altman plots show similar distribution of biases for both DBS 
methods. Specifically, bias for novel and current methods cluster around zero for both 
GBP5 and DUSP3, with greater bias detected at lower delta Ct values. In contrast, bias for 
novel and current methods cluster above zero for KLF2, with greater detected bias at higher 







These findings suggest that our novel methods in DBS collection and storage had a neutral 
effect on performance for detection and a positive effect on the quantification of mRNA 
by RT-PCR when compared with current DBS methods recommended by CDC. As 
previously noted, even a neutral effect on assay results would be valuable as our novel 
methods eliminate one of the biggest impediments to wider adoption of DBS sampling in 
the field, specifically, the requirement for extended open-air drying. By enabling 
immediate storage after sample collection, DBS can be used in a range of complex 
environmental settings, including tropical climates, remote or austere environments, and 
occupational settings, to name a few. In each of these environments, the technical 
requirement for extended (3h) open-air drying may often be infeasible and could thus 
prohibit use. Moreover, the elimination of extended open-air drying also substantially 
reduces the chance of sample contamination. The present findings provide an opportunity 
to significantly broaden the array of fields in which microsampling is employed, and may 
enable wider adoption of DBS sampling in non-traditional settings such as remote, austere, 
and occupational environments.  
 
Though improvements in quantification over current DBS methods were modest, and 
differences between novel DBS and gold standard methods clearly remain, it should be 
noted that our study design worked against detecting any material advantages for the novel 
DBS approach because the laboratory setting employed here lacked many of the ecological 
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challenges that complicate analysis of field-collected biosamples. For example, this 
experiment was conducted in a lab-based environment under conditions of moderate 
humidity (limiting the hydrolytic advantage of immediate storage relative to extended 
drying times).  This experiment also compared novel DBS methods not just against current 
DBS methods but also with gold standard venipuncture sampling. The gold standard 
methodology benefited from a substantially greater sample volume collected directly into 
a vacutainer with a stabilizing agent specific for RNA. The gold standard method also 
benefited from its requirement to freeze samples shortly after collection, whereas both 
novel and current-method DBS samples were stored under ambient conditions for 2 weeks 
prior to RNA extraction and analysis. Despite the technical advantages for the gold 
standard sampling method (which would not be feasible in many field settings), novel and 
standard DBS assays showed reasonable quantitative correspondence with gold standard 
results, particularly for the transcript that showed the widest range of intrinsic biological 
variation (i.e., GBP5, which showed ~4 times greater magnitude inter-individual variation 
than did other assayed transcripts).   
 
The primary advantages of our novel DBS methods over current DBS methods are their 
ability to dry samples more quickly, and thereby remove some of the variation in drying 
conditions, while also minimizing potential sample contamination.  Each of these 
advantages was reduced in the present laboratory setting. However, under the more 
challenging and variable conditions of field collection, these advantages should in principle 
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reduce the technical variation or noise associated with current DBS collection and storage 
methods, and thereby increase the assay signal-to-noise ratio by providing a more stable 
environment. It is reasonable to expect that the observed advantage of novel DBS methods 
would be more evident in high-humidity field environments where drying conditions 
would be more variable and humidity more deleterious to RNA integrity [8, 40-42]. 
Follow-on studies with field application of novel methods may help clarify the analytic 
impact of these advantages over current methods. 
 
Performance in mRNA detection suggests that novel DBS methods provide a suitable 
sampling modality when qualitative detection alone is the priority. There are a wide range 
of nucleic acid-based amplification tests available for infectious disease diagnostics, many 
of which are most prevalent in tropical or austere environments where traditional sampling 
modalities are more problematic [43]. Use of novel methods could also allow for 
substantial improvements in the quality and availability of infectious disease diagnostics 
in remote or other vulnerable populations where access to basic diagnostic services remains 
constrained [8-9, 17, 43].  
 
Performance improvements in the quantification of mRNA abundance were less 
convincing for the novel DBS methods, particularly for 2 of the 3 target gene transcripts 
(i.e., DUSP3 and KLF2). These 2 transcripts are notable in showing substantially less 
“true” biological variation across study participants than did GBP5, which showed more 
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impressive correlation in quantitative estimates across sampling modalities. The relatively 
poor performance of DBS methods in quantification of DUSP3 and KLF2 mRNA did not 
stem from poorer assay performance, as replicate determination CV values actually showed 
superior performance for these two assays.  Instead, visual inspection of linear regression 
scatter plots showed substantial less dispersion in the magnitude of true individual 
differences in average mRNA abundance. Correlations are essentially a ratio of “true” 
variation across individuals relative to “noise” variation stemming from sampling 
variability and/or measurement (assay) error.  Holding constant the technical accuracy of 
an assay, as the range of true biologic variation in the sampled observations goes down 
(“range restriction”), the correlation between sampling modalities will be reduced, as was 
seen here for DUSP3 and KLF2. The cause of the differences in biological variation 
between gene transcripts is less understood. However, GBP5 is known to track innate 
antiviral responses, so it is possible that the relatively large variation in average expression 
of this transcript may stem from substantial variation in the number and activity of 
subclinical viral infections [33, 44-45]. KLF2 and DUSP3 transcripts may be less sensitive 
to the same kinds of common latent viral infections and thus show relatively less true 
variation in the generally healthy sample examined here.  
 
We believe these findings bode well for the potential field application of novel DBS 
methods for two related reasons. First, as noted above, the quantitative performance of 
novel DBS methods will likely benefit from (or more accurately, suffer less from) the 
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greater technical challenges of complex environments. The primary benefit of novel DBS 
methods over current DBS methods is removal of the extended open-air drying 
requirement.  This should help reduce technical variation in field settings as novel DBS 
methods should be less impacted by contamination and/or variable desiccation rates than 
are current DBS methods. Second, it is important to note that DBS methods will inherently 
be noisier than gold standard venipuncture methods due to the reduced biosample volume 
available.  However, comparison of DBS accuracy with gold standard venipuncture sample 
accuracy is not the appropriate conceptual frame from which to consider wider adoption of 
DBS. In complex occupational and environmental settings, and especially in austere 
environments, biosampling is often not conducted at all due in large part to the technical 
and logistical infeasibility of venipuncture as well as costs associated with the immediate 
processing and storage of those samples [8, 46-47]. The appropriate reference point for 
assessing the relative value of DBS sampling is, therefore, not the more accurate 
measurements theoretically available from gold standard, but rather measurements from 
novel DBS methods compared with no measurements at all (i.e., when no gold standard 
measurement is feasible).  
 
Our study design had several limitations. First, as a proof-of-concept study, our sample 
size was relatively small compared with full bioanalytical validation studies, which would 
likely involve a minimum of 40 subjects per best practices in the scientific literature [31, 
38]. Second, as previously discussed, we conducted our study in a lab-based environment 
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under conditions of moderate humidity, which limited our ability to detect larger 
differences between novel and current methods that might have been detected under more 
variable conditions in the field. Lastly, we prepared DBS samples by precise application 
of venous blood to filter paper cards by micropipette, whereas the more common 
application of DBS, especially in field settings, would come from capillary blood by finger 
stick with direct application to filter paper cards. Though measurements from capillary 
blood are often found to be highly correlated with venous blood, the additional variability 
associated with the sampling method could introduce bias [48-49]. For our purposes, 
however, we chose to prevent introduction of bias from finger stick application by use of 
micropipette application in order to more accurately assess the differences between 
collection and storage protocols for novel and current methods (i.e., holding constant the 
blood source). This approach was justified by the fact that the present study aimed to 
measure the variation associated with collection, storage, and assay protocols per se, rather 
than the additional biological variation associated with capillary versus venous blood, 
which would apply to both modalities in the field.  
 
Given our study findings, we suggest the following three areas as immediate priorities for 
future research. First, we recommend a full bioanalytical validation of novel methods 
compared with current methods, as well as gold standard methods, not just for mRNA 
measurements, but also for other categories of biomarkers, such as genes (DNA 
polymorphisms), metabolites, lipids, and other markers of basic research, public health, 
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and clinical relevance. Second, we recommend follow-on studies with field applications to 
determine if novel methods will demonstrate improved performance over current methods 
in the field (particularly in the presence of clinically meaningful variations in health status, 
which were not present here). Third, as our novel methods were originally optimized for 
maximizing drying rate, irrespective of the target biomarker, we would suggest additional 
exploration into further optimization of novel methods that are based on analytic categories 
rather than maximal drying rates alone. It is possible, for instance, that some analytes may 




Our findings suggest our novel DBS methods had an overall neutral to positive effect on 
performance for detection and quantification of mRNA from DBS samples. We 
recommend full bioanalytic validation, and field testing of novel methods for mRNA and 

















TABLES AND FIGURES 
 
Table 4-1. Percentage of samples achieving detectable RNA above threshold levels. 
 RNA Detection 
Gene Transcript Gold Standard 
(PAXgene Tube) 
Novel Methods Current Methods 
GBP5 (n=16) 100% 100% 93.8% 
DUSP3 (n=16) 100% 81.3% 81.3% 
KLF2 (n=16) 100% 81.3% 93.8% 
GAPDH, housekeeper (n=16) 100% 93.8% 93.8% 
 
Table 4-2. Descriptive statistics for mRNA measurements. 
 Mean Delta Ct Values + Coefficient of Variation 
Gene Transcript Gold Standard 
(PAXgene) 
Novel Methods Current Methods 
GBP5 (n=14) 1.64 + 62.9% 1.14 + 137.2% 0.62 + 241.2% 
DUSP3 (n=8) 3.12 + 15.6% 2.82 + 45.2% 2.11 + 66.0% 
KLF2 (n=12) 1.20 + 38.3% 2.14 + 41.9% 1.41 + 48.0% 
 
Table 4-3. Wilcoxon matched-pairs signed rank tests for comparing mRNA 
measurements between sampling modalities. 
 P Values (significance level set at P<0.05), Number of Pairs 
Gene 
Transcript 
Novel vs. Gold Standard 
(PAXgene) 
Current vs. Gold Standard 
(PAXgene) 
Novel vs. Current 
GBP5 0.1205, n=15 0.0045, n=15 0.1575, n=14 
DUSP3 0.2810, n=13 0.0339, n=13 0.1475, n=11 




Table 4-4. Correlation statistics for mRNA measurements of novel and current DBS 
methods compared with Gold Standard (PAXgene). 
Protocol/Transcript Pearson r 95% Confidence 
Limits 
R squared P value 
Novel/GBP5 (n=15) 0.66 0.23 to 0.88 0.44 0.0070 
Current/GBP5 (n=15) 0.60 0.13 to 0.85 0.36 0.0178 
Novel/DUSP3 (n=13) 0.16 -0.43 to 0.65 0.02 0.6132 
Current/DUSP3 (n=13) 0.33 -0.28 to 0.74 0.11 0.2804 
Novel/KLF2 (n=13) -0.14 -0.64 to 0.45 0.02 0.6583 
Current/KLF2 (n=15) 0.10 -0.44 to 0.58 0.01 0.7343 
 
Table 4-5. Correlation statistics for mRNA measurements from novel DBS methods 
compared with current methods. 
Gene Transcript Pearson r 95% Confidence 
Limits 
R squared P value 
GBP5 (n=14) 0.7442 0.353 to 0.9139 0.5539 0.0023 
Novel/DUSP3 (n=11) 0.499 -0.144 to 0.8457 0.249 0.1182 
Novel/KLF2 (n=12) -0.5076 -0.8375 to 0.0935 0.2577 0.0920 
 
Table 4-6. Detected bias (Bland-Altman) for mRNA measurements from novel and 
current DBS methods compared with Gold Standard (PAXgene). 
Protocol/Transcript Bias 95% Confidence Limits 
Novel/GBP5 (n=15) -0.4827 -2.717 to 1.752 
Current/GBP5 (n=15) -0.9927 -3.267 to 1.282 
Novel/DUSP3 (n=13) -0.3923 -2.565 to 1.78 
Current/DUSP3 (n=13) -0.7115 -3.026 to 1.603 
Novel/KLF2 (n=13) 1.982 -1.142 to 5.107 





Figure 4-1. Regression analyses for mRNA measurements in novel and current 







Figure 4-2. Bland-Altman Analyses for mRNA measurements comparing DBS 
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Aim 1 – State of the Science in Dried Blood Spots 
In our attempts to systematically characterize the current state of the science for dried blood 
spots, we identified in the scientific literature nearly 2,000 unique analytes (n=1,947) 
measured by one of more than 150 different analytic methods (n=169). In our examination 
of the strengths, weaknesses, opportunities, and threats associated with potential adoption 
of DBS, we noted that the strengths of the sampling method, and especially the removal of 
the need for phlebotomy and cold chain, make DBS a valuable tool for potential application 
in the field. Problems with analyte quantification due to small sample volume, issues of 
blood hematocrit, and the requirement for highly sensitive analytic instrumentation have 
largely been obviated by recent advancements in the quality and availability of such 
technologies. While issues of differential degradation of some classes of analytes, and the 
logistical challenges, such as open-air drying, of the current DBS collection protocol 
remain, we believe these constraints will largely be resolved by continued methodological 
improvements and the fast pace of technological advancement. 
 
Aim 2 – Improved Methods for Field Collection and Storage of Dried Blood Spots 
In our efforts to facilitate the adoption of DBS sampling for complex occupational and 
environmental settings, we sought to modify the current collection protocol by designing 
novel methods for DBS collection that remove the need for open-air drying of samples. In 
doing so, we hypothesized that our novel methods would dry DBS spots in our closed-
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system kits in less than 90 minutes in conditions of low to moderate and high humidity. 
Our findings suggest that our hypothesis was correct as our novel methods demonstrated 
average drying times in conditions of moderate and high humidity of approximately 30% 
and 50% faster respectively than open-air drying times under similar conditions reported 
in the literature. These findings suggest our novel methods could be used in a range of 
complex occupational and environmental settings, and should provide a benefit in field 
collection by removal of the need for open-air drying, prevention of possible sample 
contamination, and potential overall improvements in data quality. For example, in 
humanitarian settings in the Sahel where surrounding environments can pose 
contamination risks and high humidity conditions are common, the technical noise 
associated with collection of DBS can be problematic; however, our methods should 
minimize this noise and allow for more accurate measurements in the field. 
 
Aim 3 – Improved Methods in the Collection and Storage of Dried Blood Spots for 
RNA Detection and Quantification 
In our efforts to demonstrate improvements in data quality associated with our novel DBS 
collection methods, we sought to conduct a validation of assay protocol for comparing our 
novel DBS collection methods with the current methods recommended by CDC. We 
hypothesized that our novel methods would demonstrate an overall improvement in 
performance for RNA detection and quantification from DBS samples compared with 
current methods. Our findings suggest that our hypothesis was correct. Our novel methods 
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demonstrated a comparable performance for detection, and an improved performance on 
the quantification of RNA from DBS samples. Furthermore, our findings suggest that our 
novel methods will have an even more pronounced improvement when applied in the field, 
as they will likely yield greater benefit from increased biological variation in sample 
populations, due to minimizing increases in technical and environmental noise often 
associated with field collection of biosamples. 
 




We have identified three priority areas for future research, each associated with one of the 
specific aims from this dissertation. First, associated with aim 3 (State of the Science in 
Dried Blood Spots), we believe there is a need for a follow-on review study that attempts 
to characterizes the quality of validation studies identified from our comprehensive analyte 
database. Such a review will need to incorporate assessment criteria not just for 
bioanalytical validation studies of traditional biosamples, but also for criteria specific to 
DBS, which go above and beyond the parameters required for traditional samples. For 
example, blood hematocrit and spot-to-spot variance should be considered with DBS [1-
2].  
 
Second, associated with aim 2 (Improved Methods for Field Collection and Storage of 
Dried Blood Spots), we believe there is a need for a more comprehensive approach to 
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optimization of our novel methods whereby inclusion of additional evaluation parameters 
specific to problematic classes of analytes might be considered. For example, some 
analytes in DBS samples are degraded due to oxidative processes resulting from exposure 
to atmospheric oxygen while drying [3-7]. While our novel methods may reduce overall 
oxygen exposure compared with open-air drying, they do not completely remove oxygen 
exposure. Modification to our methods might be considered for resolving the issue of 
oxygen exposure. Additionally, our novel methods were developed to maximize the rate of 
drying, however, it may be the case that some classes of analytes demonstrate greater 
stability when dried at slower rates. This would need to be investigated.  
 
Third, associated with aim 3 (Improved Methods in the Collection and Storage of Dried 
Blood Spots for RNA Detection and Quantification), we believe our findings provide 
sufficient evidence to justify a full bioanalytic validation of our novel methods as well as 
immediate adoption by researchers in field settings where the alternative to data collected 
from samples under our novel methods is no data at all, which is often the case in complex 
occupational and environmentally challenging settings [8-9]. 
 
Public Health Implications 
Review findings for our State of the Science in DBS manuscript documented the extent to 
which DBS could inform epidemiological and biomedical research, and demonstrated a 
wide range of current and potential applications in public health and clinical medicine. 
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Experimental findings for our novel methods in papers 2 and 3 could further expand the 
potential range of applications, particularly for those purposes for which DBS are already 
in use, such as newborn screening and population-based sampling in austere environments, 
as well as in settings where biosampling has been historically constrained due to either cost 
or feasibility, such as complex occupational and environmentally challenging settings. 
Where DBS is already in place, our novel methods should help reduce technical variation 
associated with the current sampling methodologies, which could significantly improve 
data quality. Where biosampling has historically been constrained due to cost or feasibility, 
we believe our novel methods provide a low cost and technically feasible option for 
adoption of biosampling in settings where no sampling, and consequently, no data are 
available. Should our methods be adopted in these areas, DBS can provide a valuable tool 
for assessing health and disease status, occupational and environmental exposures, and 
conducting both retrospective and longitudinal data collection for research and health 
surveillance purposes. Furthermore, our findings justify a full bioanalytical validation of 
our novel methods, which could pave the way for their integration into existing health 
systems as a clinical resource for enabling home-sampling, generally, and sampling in 
remote or otherwise underserved populations, more specifically. Adoption in these areas 







It is clear from our findings that DBS provide researchers and practitioners with a wide-
ranging tool for a variety of potential applications in complex occupational and 
environmental settings. Though remaining challenges are substantial, they are not 
intractable, and the recent history of DBS use seems to suggest that the real question 
surrounding the enduring issues is not “if” they will be resolved, but “when”. As this 
dissertation has demonstrated, even some of the longest held technical challenges, such the 
hematocrit effect, or in the case of this dissertation, the requirement for open-air drying, 
can be resolved simply and with existing or emerging technologies. Recent trends may also 
play a role in the eventual routine adoption of DBS. As current economic and social 
pressures continue to shift the provision of health services away from the traditional clinical 
or laboratory settings, and as researchers and practitioners continue to extend the reach of 
biosampling to remote, underserved, or otherwise vulnerable populations, DBS will likely 
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Preliminary Search - PubMed (~9,041) 
Date run:  9/3/15  (9,238 hits – only 9,237 imported.  Tested twice – must be a 
duplicate) 
"Dried Blood Spot Testing"[Mesh] OR blood spot*[tw] OR bloodspot*[tw] OR "dried 
blood"[tw] OR Guthrie[tw] OR "blood sampling paper"[tw] OR "filter paper blotter"[tw] 
OR "filter paper disk"[tw] OR "dried filter paper"[tw] OR PKU card*[tw] OR Blood 
Collection Card*[tw] OR ((Filter paper*[tw] OR filter card*[tw] OR filter plate*[tw]) 
AND (blood*[tw] OR "Blood"[Mesh] OR "blood" [Subheading])) OR (("Paper"[Mesh]) 
AND ("Blood Specimen Collection"[Mesh] OR "Blood Chemical Analysis"[Mesh] OR 
"Tandem Mass Spectrometry"[Mesh] OR "Biological Markers/blood"[Mesh] OR "Blood 
Preservation"[Mesh])) OR ("Blood Specimen Collection"[Mesh] AND dried[tw]) OR 
"Blood Stains"[Mesh] OR bloodstain*[tw] OR blood stain*[tw] OR (DBS[tw] AND 
("blood"[Subheading] OR "blood"[All Fields] OR "blood"[MeSH Terms] OR "mass 
screening"[MeSH Terms] OR "screening"[tw])) 
  
Final Search Strategy - Review of Reviews/Validation Studies/Evaluation Studies 
Date:  11/16/15, 1,138 hits 
Reviews – filter 
Systematic Reviews - filter 
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"Validation Studies as Topic"[Mesh] OR "Validation Studies" [Publication Type] OR 
"Evaluation Studies" [Publication Type] OR validation[tw] 
************************************************************************
******** 
Embase  (~12,194) 
Date run:  12,520 hits 
'dried blood spot testing'/exp OR 'blood stain'/exp 
((blood NEXT/1 spot*) OR bloodspot* OR "dried blood" OR Guthrie OR "blood 
sampling paper" OR "filter paper blotter" OR "filter paper disk" OR "dried filter paper" 
OR (PKU NEXT/1 card*) OR ("Blood Collection" NEXT/1 Card*) OR bloodstain* OR 
(blood NEXT/1 stain*)):ti,ab 
((Filter NEXT/1 paper*) OR (filter NEXT/1 card*) OR (filter NEXT/1 plate*)):ti,ab 
AND (blood*:ti,ab OR 'blood'/exp) 
('paper'/exp) AND ('blood sampling'/exp OR 'blood specimen collection kit'/exp OR 
'blood analysis'/exp OR 'tandem mass spectrometry'/exp OR 'blood storage'/exp) 
(('blood sampling'/exp OR 'blood specimen collection kit'/exp) AND dried:ti,ab) 
DBS:ti,ab AND ('blood'/exp OR blood:ti,ab OR 'screening'/exp OR screening:ti,ab) 
***************** 
Review of Reviews/Validation Studies/Evaluation Studies 
Date:  11/16/15, 1,063 hits 
Filters – Review, Systematic Reviews, Meta-Analysis 
 
 164 





Date run:  9/3/15.  1,048 without PubMed.  (2,974 with all results) 
All combined: 
"blood spot" OR "blood spots" OR "blood spotted" OR bloodspot* OR "dried blood" OR 
Guthrie OR "blood sampling paper" OR "filter paper blotter" OR "filter paper disk" OR 
"dried filter paper" OR "PKU card" OR "PKU cards" OR "Blood Collection Card" OR 
"Blood Collection Cards" OR bloodstain* OR "blood stain" OR "blood stains" OR 
"blood stained" OR (("Filter paper" OR "filter papers" OR "filter card" OR "filter cards" 
OR "filter plate" OR "filter plates") AND blood*) OR (Paper AND ("Blood Specimen 
Collection" OR "Blood Chemical Analysis" OR "Tandem Mass Spectrometry" OR 
"Biological Markers/blood" OR "Blood Preservation")) OR ("Blood Specimen 
Collection" AND dried) OR (DBS AND (Blood OR Screening)) 
  
11/16/15:  Validation Studies – 29 hits, none relevant 
("blood spot" OR "blood spots" OR "blood spotted" OR bloodspot* OR "dried blood" 
OR Guthrie OR "blood sampling paper" OR "filter paper blotter" OR "filter paper disk" 
OR "dried filter paper" OR "PKU card" OR "PKU cards" OR "Blood Collection Card" 
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OR "Blood Collection Cards" OR bloodstain* OR "blood stain" OR "blood stains" OR 
"blood stained" OR (("Filter paper" OR "filter papers" OR "filter card" OR "filter cards" 
OR "filter plate" OR "filter plates") AND blood*) OR (Paper AND ("Blood Specimen 
Collection" OR "Blood Chemical Analysis" OR "Tandem Mass Spectrometry" OR 
"Biological Markers/blood" OR "Blood Preservation")) OR ("Blood Specimen 
Collection" AND dried) OR (DBS AND (Blood OR Screening))) AND (validation) 
************************************************************************
******** 
SciFinder  (lrosman1; Welch123) 
https://scifinder.cas.org/help/scifinder/R36/index.htm  
Refine:  "CAPLUS" 
All combined:  5,090 – remove duplicates:  5,045 
"dried blood spot"  (2,096) 
"dried bloodspot"  (21) 
Guthrie (554) 
"dried bloodstain"  (78) 
"dried blood stain"  (171) 
"dried blood sample"  (2,179) 
("Blood Specimen Collection" and dried)  (136) 
(DBS and Blood)  (925) 
(DBS and screening) (323) 
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"PKU card" (5) 
"Blood Collection Card" (704) 
DBS biomarker  (36) 
DBS marker  (186) 
******************************** 
11/16/15:  Validation studies/Reviews:  575 total 
Validation 
"dried blood spot"   376 
"dried bloodspot"  1 
"dried blood sample"  256 
Review 
"dried blood spot"   142 
"dried bloodspot"  1 

































APPENDIX 3-A - OPTIMIZATION EXPERIMENT 
 
 
OPTIMIZATION EXPERIMENTAL METHODS & RESULTS 
 
 
Goal: The goal of the optimization experiments was to determine an optimal amount of 
molecular sieve for drying the internal conditions of our novel DBS kits as based on the 
volume of space within the container, choice of filter paper card, and likely moisture 
content introduced into the closed system by inclusion of a freshly spotted filter paper card.  
 
Outcome Measure: The outcome measure of interest for optimization experiments was 
Time to Decline (TTD), defined here as the minutes required from the start of the 
experiment for the relative humidity (RH) inside kits to begin to reduce suggesting 
desiccant is effectively controlling internal moisture and drying the environment around 
the spotted filter paper card.  
 
Materials: Kit containers were procured directly from Elemental Container (product # 
0075152); 10 g molecular sieve desiccant packets (product # 02-00041AG19) and 
Whatman 903 cards (product # 10531018) were procured from Sigma-Aldrich; wireless 
bluetooth enabled RH/temperature HOBO data loggers (product # MX1101) were procured 
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from ONSET; and 200 microliter adjustable pipettes (product # 3121000082) were 
procured from Eppendorf.   
 
Process: Increasing amounts of molecular sieve were included inside kit containers along 
with filter paper cards freshly spotted with 4 drops of 30 uL amounts of water by 
micropipette, and a HOBO sensor for measuring relative humidity (RH) and temperature 
inside the closed-system containers. External temperature and humidity were controlled at 
25.6℃ and 35% RH respectively. The moisture inside the kit containers was measured 
throughout experimentation with relative humidity by HOBO sensors at 1-minute 
increments. To carry out the experiment, investigators started the data logger, then spotted 
filter paper cards, and immediately stored the card inside the kit along with a pre-defined 
amount of molecular sieve, and an ONSET data logger. Experiments were carried out under 
ambient lab conditions (25.6℃ and 35% RH), and included 6 replicates. Temperature and 
RH conditions in the lab were monitored throughout experiments. Experiments were 
carried out for 24 hours, after which time containers were unsealed, HOBO sensors 
stopped, and data downloaded in Excel and CSV formats. Data was then imported into 
Stata version 13.1 for analysis. Each experiment contained a pre-defined amount of 





Analysis: The mean and standard deviation for TTD of each experimental run (i.e. 6 
replicates of pre-defined 10 gram molecular sieve amount) was calculated. A two-sample 
t-test for comparing mean TTDs between experimental groups was used for determining 
the optimal amount of sieve, which is defined here as the lowest 10 gram increment of 
sieve with a significantly faster TTD above the previous 10 gram increment, plus 10 grams 
excess sieve for long-term storage. The 10 grams of excess sieve was included in the kit’s 
optimal sieve amount in order to maintain a near moisture free environment over extended 
periods of storage. Near moisture free environment is defined here as a detected RH level 
of less than 0.01%. 
 
Results 
The lowest incremental amount of molecular sieve with a significantly faster TTD 
compared with the previous increment was 30 grams (df = 10, t = 3.77, p = 0.0037, 95% 
CI;  Table A-1). Based on predefined criteria for optimal desiccant quantity, investigators 
selected 40 grams molecular sieve as optimal amount of desiccant for inclusion in kits. 40 
grams molecular sieve represents 10 grams in excess of the lowest sieve amount with a 





Table A-1. Optimization experimental findings for mean TTD with two sample t-test 
comparisons between experimental group means. 
Amount 
desiccant 
Mean TTD, standard 
deviation (n=6) 
Two sample t test 
df = 10, 95% CI 
10 grams 33.50 minutes, 3.51 Not applicable  
20 grams 31.17 minutes, 1.33 t = 1.52, p = 0.1585 (compared w/ 10 g)  
30 grams 26.83 minutes, 2.48 t = 3.77, p = 0.0037 (compared w/ 20 g)  
40 grams 28.67 minutes, 0.82 t = 1.72, p = 0.1166 (compared w/ 30 g)  
50 grams 27.17 minutes, 1.72 t = 0.27, p = 0.7925 (compared w/ 30 g)  
60 grams 23.67 minutes, 4.37 t = 1.54, p = 0.1536 (compared w/ 30 g)  
70 grams 25.33 minutes, 3.27 t = 0.90, p = 0.3915 (compared w/ 30 g)  
80 grams 29.50 minutes, 1.87 t = 2.10, p = 0.0620 (compared w/ 30 g)  
90 grams 32.50 minutes, 2.07 t = 4.29, p = 0.00165 (compared w/ 30 g)  
















                                                     
5 The difference in TTD for 90 grams compared with 30 grams was significant, however, the mean TTD 
for 90 grams was significantly slower than 30 grams and is therefore not considered optimal. 
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SOP – 45- PAXgene Blood RNA Isolation 
 
PAXgene Blood RNA Tube: Catalog # 762165 (Qiagen/BD Company) 
PAXgene Blood RNA Kit: Catalog# 762164 762165 (Qiagen/BD Company) 
 
NOTE: Store the PAXgene Blood RNA tube upright @ RT for a minimum of 2 hrs and a 
maximum of 72 hrs before processing or transferring to refrigerator (2°C - 8°C) or freezer 
(-20°C).  Stand the tubes upright in a wire rack.  Do not freeze in a Styrofoam tray as this 
may cause the tubes to crack. 
 
Performance Characteristics: RNA profile remains stable for 3 days @ RT (18°C - 
25°C), 5 days @ 2°C - 8°C, or for a minimum of 50 months @ -20°C or -70°C/-80°C.  
  
Things to do before starting 
● If the PAXgene Blood RNA Tube was stored at 2-8°C or -20°C or -70°C after 
blood collection, first equilibrate it to room temperature, and then store it at room 
temperature for 2 hours before starting the procedure. 
● Buffer BR4 is supplied as a concentrate.  Before using for first time, add 4 volumes 




1.   Close the QIAcube door, and switch on the power switch. 
2.   Open the QIAcube door, and load the necessary reagents and plasticware into 
the QIAcube, pages 29-39 in the PAXgene Blood RNA Kit Handbook.  To 
save time, loading can be performed during one or both of the following 10 
min centrifugation steps (steps 3 and 5). 
3.   Centrifuge the PAXgene Blood RNA tube for 10 min @ 3000-5000 x g using 
a swing-out rotor.  It will be Program#3 in the Sorval ST 40R centrifuge. 
NOTE: Ensure that the blood sample has been incubated for a minimum of 2 
hrs @ RT, in order to achieve complete lysis of blood cells. Excessive 
centrifugation speed (over 10,000 RCF) may cause PAXgene Blood RNA 
Tube breakage. 
4.   Remove the supernatant by decanting or pipetting.  Add 4 ml RNAse-free 
water to the pellet, and close the tube using a fresh secondary BD Hemogard 
closure (supplied with the kit). 
5.   Vortex until the pellet is visibly dissolved, and centrifuge for 10 min @ 3000-
5000 x g (Program#3). Remove and discard the entire supernatant.  
NOTE:  Incomplete removal of the supernatant will inhibit lysis and dilute the 
lysate, and therefore affect the conditions for binding RNA to the PAXgene 
membrane. 




7.   Pipet the sample into a 2 ml safe-lock tubes processing tube. 
8.   Load the open 2ml processing tubes containing sample into the QIAcube 
shaker (see Fig. 13, pg30 and Fig.17, pg33).  The sample positions are 
numbered for ease of loading.  This enables detection of samples during the 
load check.  
NOTE: Make sure that the correct shaker adapter (Shaker Adapter marked 
with a “2”) is installed. 
9.   Close the QIAcube instrument door. 
10.  Select the “PAXgene Blood RNA Part A” protocol, and start the protocol.  
Follow the instructions given on the QIAcube touchscreen.  NOTE: Make sure 
that both program parts (part A and part B) are installed on the QIAcube 
instrument.  
NOTE: The QIAcube will perform load checks for samples, tips, rotor 
adapters, and reagent bottles. 
11.  After the “PAXgene Blood RNA PartA protocol is finished, as indicated by a 
display message, open the QIAcube instrument door.  Remove and discard the 
PAXgene RNA spin columns from the rotor adapters and the empty 
processing tubes from the shaker.  NOTE: During the run, spin columns are 
transferred from the rotor adapter position 1 (L1) to rotor adapter position 3 
(L2) by the instrument. 
 
 175 
12.  Close the lids of all 1.5 ml microcentrifuge tubes containing the purified RNA 
in the rotor adapters.  Transfer the 1.5ml microcentrifuge tubes into the 
corresponding positions in the QIAcube shaker adapter. 
13.  Close the QIAcube instrument door. 
14.  Select the “PAXgene Blood RNA Part B” protocol, and start the protocol.  
Follow the instructions given on the QIAcube screen.  
NOTE:  This program incubates the samples @ 65°C and denatures the RNA 
for downstream applications.  Even if the downstream application includes a 
heat denaturation step, do not omit this step.  Sufficient RNA denaturation is 
essential for maximum efficiency in downstream applications. 
15.  After the “PAXgene Blood RNA Part B” program is finished, as indicated by 
a display message, open the QIAcube instrument door.  Immediately place the 
microcentrifuge tubes containing the purified RNA on ice.  
NOTE:  Do not let the purified RNA remain in the QIAcube.  Since the 
samples are not cooled, the purified RNA can be degraded.  Unattended 
overnight sample preparation runs are therefore not recommended. 
16.  Measure the RNA concentration (e.g., using PicoGreen dye fluorescence or 
spectrophotometry on a Nanodrop instrument). 
17.  If the RNA samples will not be used immediately, store at -20°C or -70°C.  
18.  Remove the reagent bottle rack from QIAcube worktable, and close all bottles 
with the appropriately labeled lids.  Buffer in bottles can be stored @ RT for 
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up to 3 months.  Remove and discard remaining reagents in the processing 
tubes in the QIAcube microcentrifuge tube slots.  Remove and discard rotor 
adapters from the centrifuge.  Empty the QIAcube waste drawer.  Close the 


























SOP – 44- Dried Blood Spot RNA Isolation 
 
1.   Take the dried blood spot sample (Whatman filter paper), place on the small 
plastic weighing boat. Cut out all available blood spots using a sterile sharp 
surgery scissors. Further cut into little strips of 0.3 cm2.  Place surgery 
scissors in the 50mL Falcon tube with 100% alcohol to decontaminate. 
2.   Place the cut out blood spot using a forceps in a 2ml safe-lock 
microcentrifuge tube. 
3.   Add 360-370 ul RLT buffer and completely submerge the filter paper. 
4.   Turn On QIAcube machine. 
5.   Select Tools. Select Shaker. Press Edit. 
6.   Time = 1800 sec 
Temp = 37°C 
Frequency = 1000 rpm 
7.   Incubate the sample for 30 min @ 37°C with agitation using the QiaCube 
Shaker @ 1000 rpm. 
8.   Transfer RLT sample (360- 370ul everything including the cut up filter 
paper) into the QIAshreddrer. Spin it for in the microcentrifuge for 1 min, 
maximum speed. 




10.  Proceed to RNA extraction using the QIAcube RNeasy Micro Kit (cat. # 
74004). Choose the QiaCube  Protocol  under RNA and choose RNeasy 
Micro kit (with the DNase). 
11.  Do not Nano drop RNA sample (the very low RNA concentration will 





































SOP – 24- QuantiTect Probe RT-PCR Procedure 
 
 
1.    Preparation of reagents: 
 
1.1  Always wear gloves when handling reagents.  Prepare ice bucket before getting 
reagents from -20 freezer.  Place reagents on ice.  Don’t touch the enzyme’s tube 
or inside the tube with bare hands! 
1.2  Wear appropriate PPE (lab gown, goggles, mask, gloves) 
1.3  Vortex reagent-mixture before use. 
1.4  QuantiTect Probe RTPCR Kit - cat# 204445 (Qiagen) 
1.5  Optical PCR Plate (96 well) – cat# 2239441 (Bio-Rad) 
1.6  Microseal “B” Film – cat# MSB1001 (Bio-Rad) 
2.    Preparation of Master Mix: multiply MM by the number of rxns 
QuantiTect Probe MM (2X)                    = 12.5 uL 
RNAse Free H2O                                  = 6.0 uL 
Taqman Gene Expression Assay (20X) = 1.25 uL 
RT mix                                                     = 0.25 uL 
RNA template (1pg-500ng/rxn)             = 5 uL 
                                                                        = 25 uL 




4.    Add 5ul of RNA sample to the bottom surface of the optical reaction plate. 
5.    Add 20ul of the Master Mix to each well containing 5ul of RNA template. 
6.    Place the optical tape on top of the wells.  Don’t touch the top with gloves.  Use 
the flat edge tool to seal. 
7. Place the PCR samples in the Bio-Rad iCycler machine. 
7.1 Before running the machine, make sure that on the bottom of the screen it says, 
“HOST CONTROL MODE” to make sure the machine is ready to take pictures of 
the reactions. 
8.  Reaction Protocol 
8.1 Review SOP-23b- BioRad iCycler RT-PCR Machine before using the machine. 
8.2 Use QuantiTectPCR.tmo or AB 1-Step RTPCR.tmo for running the Reverse 
Transcriptase PCR. 
9.  When finished with the PCR reaction, don’t take samples back in the PCR/laminar 
hood. 
9.1 Open the iCycler lid and check the labels on the plate.  Verify the primer/probe used 
for the PCR run, samples (RNA/DNA), study name, and the date. 
9.2 Don’t throw PCR products away, wrap them up in foil and place in the fridge with your 
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